key: cord-0034063-3fm3io95
authors: nan
title: 43. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin
date: 2012-08-30
journal: Wien Klin Wochenschr
DOI: 10.1007/s00508-012-0234-x
sha: a0b70b3bc7cf8f653b01f20c4205ee1277fa381e
doc_id: 34063
cord_uid: 3fm3io95

nan

Background: Inhibition of platelet reactivity with aspirin is standard therapy after percutaneous intervention (PTA) in peripheral arteries. Nevertheless reobstruction rate especially in the superficial femoral artery (SFA) is high. Interaction of activated platelets and the endothelium in the region of intervention could be one reason for this fact as collagen of the subendothelium is a strong activator for platelets. We therefore conducted a prospective study evaluating the platelet reactivity induced by collagen measured in the region of percutaneous intervention and its possible influence on the development of reobstruction after PTA.

Methods: A total of 30 patients were included in this prospective study. Arterial blood was taken in the PTA region immediately after intervention of the SFA. Platelet function was performed on a Lumi-Aggregometer (Chronolog 700, Chronolog Corp., Havertown, PA) using collagen (2 mg/ml) in standard concentrations and results were analyzed using the Aggrolink 8.1.2.2 software package (Chronolog). After 3, 6, 12, and 24 months duplex sonography was performed and reobstruction rate was evaluated.

Results: A total of 8 patients developed a hemodynamically relevant reobstruction (> 70 % lumen narrowing) requiring intervention in the PTA region during the 24 months follow up period. High platelet reactivity induced with collagen defined as AUC > 30 was a significant predictor for the development of a reobstruction (adjusted OR 11.8 (9.4, 14.2.) ; P = 0.04).

Conclusion: High platelet reactivity at the interventional site induced with collagen and measured with a Lumi-Aggregometer predicts development of reobstruction after PTA of the SFA.

Heparin/platelet factor 4 dependent platelet antibodies in patients undergoing angioplasty and stenting and their role for on-clopidogrel platelet reactivity (APS) and clinical presentation in the arterial system differences in body weight were already investigated. We examined the difference in the frequency of primary APS (PAPS) in VTE patients according to their BMI.

Objective: To evaluate differences in the occurrence of PAPS in VTE patients according to their BMI.

Methods: We included 998 VTE patients treated at our outpatient clinic between 2009 and 2011 in our retrospective data analysis. Thrombophilia screening including evaluation for APS (lupus anticoagulant, anti-cardiolipin and anti-B2-glycoprotein I IgG and IgM antibodies) was done in all patients.

Results: PAPS was diagnosed in 6.8 % (24/355) of normal weight (BMI < -24 kg/m 2 ) VTE patients, in 11.1 % (50/452) of overweight (BMI 25-30 kg/m 2 ) VTE patients, and in 15.7 % (30/191) of obese (BMI > _ 31 kg/m 2 ) VTE patients. Using Chi Square test the difference between groups was statistically significant (P = 0.001).

Conclusion: PAPS seems to be more frequent in overweight and obese patients and could be one further reason for the increased VTE risk in overweight patients.

Repetitive (18)F-fluorodeoxyglucose positron emission tomography: a predictive value for relapse of giant cell arteritis?

subjects who did not have significant CAD at the baseline angiography were at a 33 % (p = 0.027) increased diabetes risk. However, the relationship between CAD and incident diabetes was attenuated and no longer statistically significant after adjustment for potential confounders including metabolic syndrome (MetS) status. The MetS as diagnosed according to the current consensus definition in turn was strongly predictive of diabetes, in particular when the more selective NCEP-ATP-III waist cutoff values were applied for its diagnosis ; p < 0.001).

Conclusion: We conclude that albeit apparently not causally related to diabetes incidence, the presence of CAD indicates a strongly increased risk for incident diabetes. Repeated diabetes screening of coronary patients and targeted programs to prevent diabetes in these high-risk patients are warranted.

Grundlagen: Erniedrigte 25-Hydroxy-Vitamin D-Spiegel (25(OH)VitD) wurden häufig mit erhöhten Mortalitätsraten assoziiert, was derzeit kontroversiell diskutiert wird. Um die Kausalität dieser Assoziation zu untersuchen, führten wir eine Studie mit einer Mendelschen Randomisierung durch. Drei bekannte, mit erniedrigten Vitamin D-Spiegeln assoziierte Gen-Polymorphismen wurden dabei auf mögliche Assoziationen mit Mortalität hin geprüft.

Methodik: Genotypen des Group-specific component-Gens (GC),des 7-Dehydrocholesterol Reduktase-(DHCR7) und des Cytochrom P450 IIR-1-Gens (CYP2R1) wurden in einer prospektiven Kohorte von 3316 TeilnehmerInnen, die sich einer Koronarangiographie unterzogen hatten, analysiert. 25(OH)VitD Spiegel wurden mittels Radioimmunoassay (Diasorin) untersucht. Die wichtigsten Endpunkte waren Gesamtmortalität, kardiovaskuläre Mortalität und nicht-kardiovaskuläre Mortalität im weiteren Verlauf.

Ergebnisse: In einem linearen Regressionsmodell wurden 25(OH)VitD-Spiegel durch Alter (p < 0,001), Geschlecht (p < 0,001), GC-Genotyp (p < 0,001), CYP2R1-Genotyp (p = 0,036) und DHCR7-Genotyp (p = 0,001) signifikant determiniert. Während einer medianen Beobachtungszeit von 9,9 Jahren verstarben 955 (30 %) der StudienpatientInnen, dabei waren 619 Todesfälle die Folge kardiovaskulärer Ursachen. In einer multivariaten, mit den klassischen kardiovaskulären Risikofaktoren adjustierten Cox-Regressionsanalyse bestand kein Zusammenhang zwischen den GC-, CYP2R1-und DHCR7-Genotypen und der Gesamtmortalität, der kardiovaskulären Mortalität und der nicht kardiovaskulären Mortalität.

Schlussfolgerung: Unsere Daten zeigen, dass niedrige 25(OH) VitD-Spiegel zwar mit einem erhöhten Mortalitätsrisiko assoziiert sind, aber eine kausale Rolle aufgrund der fehlenden Assoziation der Vitamin D Insuffizienz Genotypen mit Mortalität unwahrscheinlich ist. Ob eine Vitamin D-Supplementierung Mortalitätsraten senken kann, muss daher in randomisierten klinischen Studien noch prospektiv untersucht werden.

Angiopoietin-like 4 is elevated in type 2 diabetes but is not associated with angiographically determined coronary artery disease was not correlated with waist circumference, triglycerides, HDL cholesterol, systolic blood pressure or diastolic blood pressure. ANGPTL4 was significantly higher in patients with T2DM (n = 115) than in non-diabetic subjects (28 ± 32 vs. 25 ± 38; p = 0.032); however, it was not significantly different between patients with significant CAD (n = 246) and individuals without significant CAD (p = 0.112).

Conclusion: We conclude that ANGPTL4 is positively correlated with fasting glucose and elevated in T2DM but is not significantly associated with angiographically determined CAD. Ziel: Vergleich von Vasopressin und Copeptin und deren klinische Validierung, um Copeptin bei akutem Handlungsbedarf anstatt/schneller als Vasopressin zu bestimmen.

Methodik: Von PatientInnen mit unterschiedlichen Hypophysenerkrankungen und gesunden Kontrollen werden Parallelanalysen von Vasopressin mittels kommerziell erhältlichem Radioimmunoassay und Copeptin mittels immunoluminometrischem Assay (Fa.Brahms) in Doppelbestimmungen durchgeführt.

Ergebnisse: Die Etablierung und Validierung der Copeptin-Analytik wurde nach Herstellerangaben durchgeführt und im laufenden Betrieb validiert.

Schlussfolgerung: Copeptin ist als neuer Biomarker für den Hypophysenhinterlappen präanalytisch stabiler als Vasopressin und kann nach Adaptierung im Labor einfach gemessen werden. Der Sandwich-Immuno-Assay für die Bestimmung von Copeptin ermöglicht eine rasche Messung aus Serum-oder auch Plasmaproben. The oral antidiabetic drug metformin is commonly used in the treatment of diabetes type 2 and increasingly in polycystic ovary syndrome (PCOS ) since it not only improves insulin resistance but also decreases gluconeogenesis and activates hepatic sex hormone binding globulin production. In humans, metformin is marginally metabolized and eliminated by the kidney. It is widely known that there is a great variability in the clinical response to metformin. Genetic variances determine the pharmacokinetics/-dynamics of metformin or its action. Metformin is the substrate of the organic cation transporters (Octs) Oct1 (liver specific) and Oct2 (kidney).

We analysed the incidence of 7 single nucleotide polymorphisms (SNPs) in Oct1, which is especially genetically highly polymorphic, (Oct1-1 to Oct1-7) and one SNP in the Oct2 gene in 806 Caucasian PCOS patients. Each of these variants leads to the formation of an inactive transporter allele.

The SNP Oct1-5 (originally identified in Asian cohorts) was not further investigated due to a minor allele frequency (MAF < 0.001 in our cohort. However, 17.1 % of female PCOS patients showed one inactive allele of Oct1 or Oct2, leading to decreased hepatic metformin uptake or renal reabsorption resulting in a decrease of all metformin effects and 2.2 % of PCOS patients were homozygous for Oct1 or Oct 2 SNPs (only marginal metformin uptake and no renal reabsorption) leading to none efficacy.

Oct SNPs influence the bioavailability of metformin by its hepatic uptake and renal clearance, contributing to variances in metformin efficacy. It is of increasing interest to know more about pharmacogenetically individual medication for individuals carrying variants for Oct1 and/or Oct2 in common metabolic diseases such as type 2 diabetes or PCOS to improve therapy outcomes. Anamnese und klinischer Status: Wir berichten über eine 85-jährige Patientin, die wegen allgemeiner Schwäche, Übelkeit, Erbrechen und peripherer Parästhesien das Krankenhaus aufsuchte. Aufgrund einer Osteoporose war einige Wochen zuvor eine Denosumab-Therapie eingeleitet worden. Klinisch war eine Pfötchenstellung der Hände auffällig. EKG und Labor: Im EKG fiel eine im Vergleich zu den Vor-EKGs verlängerte frequenzkorrigierte QT-Zeit auf. Sowohl das Gesamt-Kalzium (1,20 mmol/l), als auch das ionisierte Kalzium (0,36 mmol/l) waren deutlich erniedrigt. Das Albumin lag im unteren Normbereich. Der 25-OH Vitamin-D Spiegel betrug 6,1 ng/ml, das PTH 659 pg/ml. Es bestand zu keinem Zeitpunkt eine renale Funktionseinschränkung.

Weiterer Verlauf: Nach intravenöser Gabe von Kalzium besserten sich die Symptome rasch, Denosumab wurde abgesetzt. Unter Substitution mit Kalzium-und Vitamin-D Präparaten normalisierten sich in weiterer Folge die Kalzium-Werte.

Diskussion: In klinischen Studien mit Denosumab bei Patientinnen mit postmenopausaler Osteoporose wurden bislang keine Fälle von schwerer Hypokalzämie berichtet. Bei PatientInnen mit metastasiertem Mammakarzinom traten unter Denosumab allerdings mehr Hypokalzämien auf als in der Bisphosphonat-Gruppe. Kürzlich wurde außerdem ein Fallbericht über eine Patientin mit schwerer Hypokalzämie veröffentlicht, bei der zuvor eine Denosumab-Therapie aufgrund einer Osteoporose eingeleitet worden war. Wir berichten über eine 54 jährige Patientin mit MEN1, die klassische klinische Manifestationen eines primären Hyperparathyreoidismus, eines Prolaktinoms der Hypophyse und einer Raumforderung im Pankreas zeigt. Anamnestisch beschreibt die Patientin im letzten Jahr zunehmende Schwächezustände und Schweißausbrüche die sich nach Nahrungsaufnahme rasch bessern. In der laborchemischen Kontrolle zeigt die Patientin einen Nüchternblutzucker von 45 mg/dl (70-115) ohne wahrnehmbare hypoglykämische Symptomatik. Weiterführende Untersuchungen zeigen eine Raumforderung (MR-tomographisch) an der Corpus-Cauda Grenze des Pankreas mit den typischen radiologischen Kriterien eines neuroendokrinen Pankreastumor (PNET). Im Verlauf der letzten 3 Jahre findet sich eine Größenzunahme von 22 auf 27 mm im Durchmesser.

Im Rahmen der aktuellen Laborkontrolle findet sich ein Glukagonspiegel von 942 pg/ml (-250), Insulin und C-Peptid liegen im unteren Normbereich.

Auf Grund der zunehmenden Klinik und Größenprogredienz der Raumforderung im Pankreas wird eine Pankreas-Linksresektion mit Splenektomie durchgeführt. In der histologischen und immunhistochemischen Aufarbeitung zeigt sich ein 2,9 cm im Durchmesser haltender hochdifferenzierter Insulin-positiver neuroendokriner Tumor (pT-2, G-1, pN-0). Daneben findet sich ein weiterer neuroendokriner Tumor (4 mm) der keine immunhistochemische Reaktion mit Insulin, jedoch eine deutliche Reaktion mit Glukagon zeigt. Parathyroid hormone and 24-hour ambulatory blood pressure: cross-sectional data of hypertensive patients from the Styrian Vitamin D Hypertension Study Background: Parathyroid hormone (PTH) is an emerging cardiovascular risk factor and exerts various effects on the cardiovascular system that may increase blood pressure. We aimed to evaluate the largely unknown association between PTH and 24-hour ambulatory blood pressure (ABP) in a cohort of hypertensive patients.

Methods: 24-hour ABP measurement was performed in 121 hypertensive patients derived from a tertiary care centre. PTH-levels in plasma were measured using ElectroChemi Luminescence Immunoassay (ECLIA).

Results: 24-hour ABP measurements and plasma PTH levels were available in 121 subjects, (age: 59.7 ± 10.1 years; 53.1 % females) with a mean 24 hours s systolic and diastolic blood pressure of 130 ± 13 mmHg and 78 ± 9 mmHg, respectively. Mean plasma PTH was 55.6 ± 22 pg/ml.

In Pearson's correlation analyses we found a significant correlation of PTH plasma levels and mean nighttime systolic blood pressure (r = 0.214, p = 0.018) and a nonsignificant association with mean 24 hours systolic blood pressure (r = 0.185, p = 0.087), but not with measures of diastolic blood pressure. In multiple linear regression analyses with the independent variables age, gender and body mass index (BMI) included as possible confounding factors, we found an even stronger association between plasma PTH and mean nighttime systolic blood pressure (beta coefficient = 0,229, p = 0,013). This result remained significant even after additional adjustment for 25-hydroxyvitamin D levels.

Conclusion: PTH and nighttime systolic ABP are significantly correlated, even after adjustment for possible confounding factors. Further examination is needed to evaluate whether PTH-modifying therapies impact on blood pressure and cardiovascular risk.

Responses of osteocalcin to oral glucose load in insulin-resistant and non-insulin-resistant women Background: Osteoblast-produced osteocalcin (OC) seems to play a role in energy metabolism and in the regulatory circuit between pancreas and osteoblasts. The aim of this cross-sectional study was to evaluate the effect of a 75 g oral glucose tolerance test (OGTT) on total OC, undercarboxylated osteocalcin (ucOC), and carboxylated osteocalcin (cOC) in insulin-resistant (IR) and noninsulin-resistant (nonIR) premenopausal women. Further, the relationship of changes in total OC, ucOC, and cOC with the area under the curve insulin (AUCinsulin) and Matsuda index were examined.

Methods: 105 premenopausal women underwent OGTT. Of these, 21 were IR (HOMA-IR > 2) and 84 were nonIR. Changes in total OC, ucOC, and cOC were evaluated 30, 60, and 120 min after glucose load.

Results: IR women had significantly lower levels of total OC, cOC, and ucOC at baseline. In nonIR women, total OC decreased by 20.7 % from 18.4 ng/ml [14.8-24.9 ] at baseline to 14.6 ng/ml [10.9-17.8] after 120 min; ucOC decreased by 21.9 % from 3.2 ng/ml [2.3-4.6] to 2.5 ng/ml [1.7-3.5]; cOC decreased by 27.0 % from 15.2 ng/ ml [12.3-20 .6] to 11.1 ng/ml [9.0-15.1] (p < 0.001, respectively). In IR women, neither of these parameters decreased significantly. In stepwise linear regression analyses after adjusting for age and BMI, the declines in OC and cOC upon glucose load were predictors of AUCinsulin (DOC: beta = 0.301, p = 0.001; DcOC: beta = 0.315, p < 0.001) and Matsuda index (ΔOC: beta = − 0.235, p = 0.003; ΔcOC: beta = − 0.245, p = 0.002).

Conclusion: Glucose intake in nonIR women has a shortterm lowering effect on the levels of OC, ucOC, and cOC, while in IR women these parameters seem constantly suppressed. These results suggest the existence of insulin resistance in osteoblasts and reflect the interaction of bone and glucose metabolism. Background: Janus kinase (JAK) 3 is involved in cytokine receptor-mediated intracellular signal transduction. Inhibition of JAK3 protects beta-cells from cytokine toxicity and has been shown to delay the onset of diabetes in the mouse model. The influence of JAK3 single nucleotide polymorphisms (SNPs) on diabetes risk or on diabetes-related metabolic traits is unknown.

Methods: We therefore investigated the association of JAK3 tagging SNP rs3212780 (C > T) with metabolic phenotypes and type 2 diabetes (T2DM) in a cohort of coronary patients including 1220 non-diabetic subjects and 375 patients with T2DM, totally comprising 1595 individuals.

Results: Among non-diabetic subjects SNP rs3212780 was significantly associated with HbA1c (CC: 5.8 ± 0.4, CT: 5.7 ± 0.4, TT: 5.6 ± 0.4 %; p = 0.001), fasting glucose (CC: 5.4 ± 0.7, CT: 5.3 ± 0.7, TT: 5.5 ± 1.1 mmol/L; p = 0.010), and HDL-cholesterol (CC: 55 ± 17, CT: 55 ± 16, TT: 51 ± 16 mg/dL; p = 0.009), as well as with total cholesterol (CC: 212 ± 44, CT: 206 ± 46, TT: 196 ± 48 mg/dL; p = 0.002) and LDL-cholesterol (CC: 134 ± 37, CT: 131 ± 40, TT: 124 ± 42 mg/ dL; p = 0.013). In patients with T2DM, the JAK3 variant was significantly associated with fasting glucose (CC: 8.3 ± 2.7, CT: 8.7 ± 2.8, TT: 7.4 ± 1.9 mmol/L; p = 0.036). The association between SNP rs3212780 and T2DM did not reach statistical significance (allelic odds ratio = 1.18 [0.98-1.40]; p = 0.076).

Conclusion: We conclude that JAK3 tagging SNP rs3212780 is significantly associated with phenotypes conferring an increased cardiometabolic risk, at least in non-diabetic coronary patients. The association between rs3212780 and the risk of T2DM warrants further investigation.

Serum omentin is neither associated with the metabolic syndrome nor with angiographically determined coronary artery disease Background: Some recent small studies have decribed associations of the new adipocytokine omentin with the metabolic syndrome (Met ) and with cardiovascular disease. However, data still are very scarce.

We therefore measured serum omentin in 395 patients undergoing coronary angiography for the evaluation of established or suspected stable CAD; the MetS was defined according to NCEP-ATPIII criteria; significant CAD was diagnosed when coronary stenose ≥ 50 % were present.

Results: Omentin was positively correlated with age (r = 0.170; p < 0.001) but did not show significant correlations with waist circumference, fasting glucose, HDL cholesterol, triglycerides, systolic blood pressure, or diastolic blood pressure; it was similar in MetS patients (n = 118) as in subjects without the MetS (15 ± 21 vs. 14 ± 15 ng/ml; p = 0.460). Omentin also did not differ significantly between patients with significant CAD (n = 190) and those without significant CAD (14 ± 19 vs. 15 ± 15 ng/ml; p = 0.233). When both, MetS and CAD status were considered, omentin similar in MetS patients as in subjects without the MetS both among those who had significant CAD (15 ± 13 vs. 15 ± 13 ng/ml; p = 0.482) and among those who did not have significant CAD (16 ± 30 vs. 14 ± 15 ng/ml; p = 0.876); it further did not differ significantly between patients with significant CAD and subjects without significant CAD among MetS patients (p = 0.321) nor among subjects without MetS (p = 0.452).

Conclusion: We conclude that omentin is neither associated with the MetS nor with angiographically determined CAD. Omentin therefore does not appear to be a useful marker of cardiometabolic disease.

Die Rolle der Schilddrüse beim polyzystischen Ovar-Syndrom Grundlagen: Das Polyzystische Ovar-Syndrom (PCOS ) ist eine der häufigsten endokrinologischen Erkrankungen bei Frauen im gebärfähigen Alter. Viele der Betroffenen leiden auch unter Schilddrüsenerkrankungen. Ziel der Arbeit war es, die Prävalenz von Schilddrüsenerkrankungen bei Patientinnen mit PCOS zu untersuchen. Weiters wurde analysiert, ob zwischen PCOS-Patientinnen mit und ohne Schilddrüsenerkrankung Unterschiede hinsichtlich endokriner und metabolischer Parameter bestehen.

Methodik: 762 PCOS-Patientinnen wurden retrospektiv auf Schilddrüsenerkrankungen untersucht. Zudem wurden 27 Frauen prospektiv laborchemisch und sonographisch hinsichtlich Schilddrüsenerkrankungen gescreent. Metabolische und endokrine Parameter wurden zwischen Patientinnen mit und ohne Schilddrüsenerkrankungen verglichen.

Ergebnisse: 29,3 % der retrospektiv und 37 % der prospektiv untersuchten Frauen wiesen eine Schilddrüsenerkrankung auf. In der retrospektiven Gruppe wiesen Patientinnen mit Schilddrüsenerkrankung eine signifikant höhere nüchtern Insulinkonzentration (9,1 mU/l vs. 7,5 mU/l; p = 0,022) und einen höheren HOMA-Index (2,2 vs. Background: Non-selective beta-blockers (NSBB) or band ligation (BL) are recommended for primary prophylaxis of variceal bleeding in patients with esophageal varices (EV). Additional alphaadrenergic blockade (by carvedilol) may increase the numbers of patients with hemodynamic response (reduction in hepatic venous pressure gradient (HVPG) of ≤ 20 % or to values < 12 mmHg).

Methods: 104 cirrhotic patients (77 % male; age: 53 ± 12; Child A/B/C: 66/30/8; etiology: alcohol: 56 %, viral: 34 %, NASH: 10 %) with EV undergoing measurement of HVPG prior and under propranolol (80-160 mg/d) were included. HVPG responders were kept P29 P30 P28 Gastroenterologie/Hepatologie abstracts ÖGIM on propranolol (PROP group), while non-responders were placed on carvedilol (6.25-50 mg/d). Carvedilol responders continued treatment (CARV group), while nonresponders to carvedilol underwent BL. Patients were followed every 3 months.

Results: 37 of 104 showed an HVPG-response to propranolol (median dose: 100 mg/d), while 10 patients did not tolerate propranolol but were started on carvedilol. Among propranolol nonresponders 56 % (38/67) finally achieved a HVPG amelioration with carvedilol (median dose: 12.5 mg/d), while 28 % (29/104) patients were finally treated with BL. The mean decrease of HVPG was significantly greater with carvedilol than with propranolol: − 19 ± 10 vs. − 12 ± 11 % (p < 0.001). During a two year follow-up, bleeding rates were recorded: PROP: 11 % vs. CARV: 5 % vs. BL: 25 % (p = 0.043). Fewer episodes of hepatic decompensation (PROP: 38 %/CARV: 26 % vs. BL: 55 %; p = 0.079) and significantly lower mortality (PROP: 14 %/CARV: 11 % vs. BL: 31 %; p = 0.046) were observed in hemodynamic responders (PROP/CARV) compared to the BL group.

Conclusion: Carvedilol leads to a significantly greater decrease in HVPG than propranolol, so the numbers of hemodynamic NSBB responders can be increased. Both propranolol and carvedilol responders show a more favourable outcome regarding primary prophylaxis of variceal bleeding, hepatic decompensation, and mortality compared to BL. Grundlagen: Bei Patienten mit Colitis ulcerosa (CU) werden Veränderungen im Mikrobiom beobachtet. Die fäkale Bakterientherapie ist ein alternativer Therapieansatz, bei der durch Applikation von Fremdstuhl das Mikrobiom modifiziert wird. Im Gegensatz zu den guten Erfolgen in großen Kollektiven bei rezidivierenden Clostridium difficile Infektion (CDI), sind Remissionen bei CU nur in einzelnen Fallberichten beschrieben.

Ziel dieser Studie war die Untersuchung der mikrobiologischen, sowie der klinischen und endokopischen Veränderungen durch fäkale Bakterientherapie bei chronisch aktiver CU.

Methodik: Bei 6 Patienten mit therapierefraktärer CU wurden einmalig ca. 400 ml filtrierter und mit NaCl verdünnter Fremdstuhl coloskopisch über das terminalen Ileum ins Colon appliziert. Endoskopische und histologische, wie auch klinische Kontrollen wurden vorher und im Verlauf von 90 Tagen durchgeführt. Die Mikrobiomanalysen wurde mittels Amplifikation der variablen Regionen der 16S RNA und anschließender Pyrosequenzierung von Stuhl-, wie auch Schleimhautproben durchgeführt.

Ergebnisse: Alle Patienten zeigten eine kurzfristige Verbesserung der Stuhlfrequenz und Konsistenz nach 2 Wochen, die jedoch nur bei 2 Patienten über 90 Tage anhielt. Bei keinem Patienten konnte eine komplette Remission erreicht werden, 2 Patienten wur-den mittels Kolektomie und einer mittels Cyclosporin-A behandelt. Es konnten keine schweren Nebenwirkungen beobachtet werden. Die Mikrobiomanalysen zeigten über den Beobachtungszeitraum von 90 Tagen eine überwiegende Annäherung des intestinalen Mikrobioms der Patientenan die des Spenders mit großen inter-individuellen Unterscheiden.

Schlussfolgerung: Durch die einmalige Durchführung einer fäkalen Bakterientherapie, kann bei chronisch aktiver CU im Gegensatz zur CDI, keine anhaltende Remission erzielt werden. Jedoch wurden durch diese Therapie längerfristige Veränderungen des Mirkobioms sowohl in den Stuhl-als auch in den Schleimhautproben beobachtet. Ergebnisse: Baseline Charakteristika (Alter, Geschlecht, BMI, Hämoglobin, Leukozyten, Thrombozyten, Lebervenendruckgradient) unterschieden sich nicht in den drei Subgruppen (CC, CG, GG). Patienten mit dem SNP GG zeigten eine schnellere Fibroseprogression (p = 0,058) und hatten einen höhere Prävalenz von fortgeschrittener Fibrose (F3/F4) (p = 0,05). Der Anteil von hepatischer Steatose und die Anzahl der Patienten mit einer Steatose von > 10 % war nicht höher bei den Patienten mit einem G Allel. Dies könnte eventuell durch die höhere Prävalenz von Insulinresistenz (HOMA-IR) in der CC Gruppe bedingt sein. Alle Subgruppen hatten ähnliche frühe virologische Ansprechraten (RVR) auf eine antivirale Therapie mit pegyliertem Interferon und Ribavirin, jedoch hatten CC Patienten ein signifikant häufigeres bleibendes virologisches Ansprechen (SVR).

Schlussfolgerung: Bei HIV-HCV koinfizierten Patienten ist das PNPLA3 G Allel assoziiert mit einer schnelleren Fibroseprogression und fortgeschrittener Fibrose. Der hohe Anteil von GT3 Patienten und Insulinresistenz könnten jedoch eventuell verzerrende Faktoren in der Gesamtpopulation sein. Der potentielle Einfluss des PNPLA3 SNP auf virologisches Ansprechen bei HIV-HCV koinfizierten Patienten sollte noch weiter untersucht werden. Patients with steatosis (> 5 %) were older (p < 0.001), had more advanced fibrosis (p = 0.022), and presented a weaker correlation between LS and HVPG (R = 0.900 vs. R = 0.743; p < 0.001). Interestingly, F4 cirrhotic patients with steatosis showed significantly lower LS than those without (25.0 vs. 41.6 kPa, p < 0.001). Cholestasis significantly increased LS (29.8 vs. 16.4 kPa, p < 0.001), while siderosis had no effect on LS (p = n.s.). The IQR of the LS measurements significantly increased in patients > 50 years old (p < 0.001), HVPG < _ 12 mmHg (p < 0.001), steatosis G2/3 (p = 0.034), ALT > 2× ULN (p = 0.027), AST > 2× ULN (p < 0.001), and METAVIR activity A2/3 (p = 0.011).

Conclusion: LS is significantly associated with HVPG and fibrosis stage. However, the presence of hepatic steatosis, cholestasis, histological necroinflammation and levels of transaminases have to be considered when interpreting results of LS. Methodik: Wir präsentieren die Daten von 100 konsekutiven Patienten, die im Zeitraum 9/2011-2/2012 bei Verdacht auf LI zur Durchführung eines H 2 -BT zugewiesen wurden und einen Selbst-bewertungsbogen komplettierten zur Erfassung des Leidensdrucks durch verschiedene Symptome (Durchfall, Verstopfung, "Rumoren", Bauchschmerzen, Blähungen, Aufstoßen, Erbrechen, Kopfschmerzen, akrales Kribbeln, Juckreiz).

Ergebnisse: Das mittlere Alter der Gesamtkohorte lag bei 39,5 (SD 15,6) Jahren, 61 % waren Frauen. Bei 34 % der Patienten wurde eine LI diagnostiziert (positiver H 2 -BT). Anamnestische Milchunverträglichkeit war in der LI-Gruppe signifikant häufiger (67,7 vs. 39,3 %, p = 0,01). Keine Unterschiede fanden sich hinsichtlich Alter, Geschlecht, Art und Schweregrad der Beschwerden und Medikamentengebrauch. In beiden Gruppen waren die häufigsten Symptome (von ≥ 80 % angegeben): Blähungen, "Rumoren", Bauchschmerzen und Durchfall. Eine zumindest mittelschwere Beeinträchtigung im Alltag (Skala ≥ 2) wurde in beiden Gruppen annähernd häufig angegeben (LI 56,7 vs. Non-LI 67,7 %, p = 0,3 Grundlagen: Der Enhanced Liver Fibrosis (ELF) Test ist eine kommerziell erhältliche Testbatterie zur nichtinvasiven Messung der Leberfibrose, basierend auf den Serumkonzentrationen von Hyaluronic Acid (HA), Procollagen-3 N-terminal Peptide (P3NP) und Tissue Inhibitor of Metalloproteinase-1 (TIMP1). Frühere Studien zeigten eine hohe Treffsicherheit dieses Tests zur Abschätzung der Leberfibrose bei chronischer Virushepatitis und Fettlebererkrankung. Ziel der gegenständlichen Untersuchung war die Bewertung des ELF Tests als Prädiktor von hepatischer Dekompensation und Mortalität bei Leberzirrhose.

Methodik: Wir untersuchten 63 konsekutive zirrhotische Patienten, welche an unsere Leberambulanz zugewiesen wurden (29 % Frauen; Alter: 58 ± 10 Jahre; Alkoholzirrhose in 64 %). Der Child-Pugh (CP) Score und das Model for End-Stage Liver Disease (MELD) wurden routinemäßig erhoben und Serumproben wurden asserviert zur Bestimmung der ELF Testparameter und Berechnung des ELF Score (Siemens Health Care, Wien). Die Patienten wurden hinsichtlich hepatischer Dekompensation und Mortalität nachverfolgt. Die prognostische Aussagekraft von ELF Score, CP Score und MELD wurde mittels ROC Analyse erhoben. Unabhängige Variablen für Dekompensation und Mortalität wurden mittels logistischer Regressionsanalyse ermittelt.

Ergebnisse: Unser Patientenkollektiv umfasste unterschiedliche Zirrhosestadien (CP-A 38 %, CP-B 43 %, CP-C 19 %); der mediane CP Score betrug 7 (6, 9), der mediane MELD 13 (10, 16) und der mittlere ELF Score 11.9 ± 1.4. Der ELF Score stieg parallel zum Zirrhosestadium an (CP-A: 10.8 ± 1.0; CP-B: 12.2 ± 1.0; CP-C: 13. Background: Patients with liver cirrhosis may develop ascites, which can further lead to a spontaneous bacterial peritonitis (SBP). Since microbial epidemiology varies, country specific data for antibacterial therapy or prophylaxis should be obtained. Moreover risk factors for complications and mortality in patients with SBP are investigated.

Methods: Demographic, laboratory and clinical data of all cirrhotic patients undergoing paracentesis at the AKH-Vienna between 2005 and 2010 were recorded. Microbiology was assessed by cultures of ascitic fluid. SBP was defined as ascites neutrophile count > 250/µL.

Results: 138 patients (68 % male, age 57 ± 12, etiology: 59 % alcohol, 28 % viral, 13 % others) had a total of 423 paracentesis. Ascites cultures were positive in 10.9 % of all paracentesis, while in 58.9 % of patients with SBP. Most common isolated species were Staphylococcus (33.6 %), Enterococcus (18.7 %), E.coli (14.4 %), Streptococcus (11.2 %), and Candida (12.1 %). ESBL (3.2 %), VRE (2.8 %) and MRSA (2.3 %) were rarely distributed. Risk factors for developing ascitic SBP were hemoglobin (p = 0.03), WBC (p = 0.03), bilirubin (p = 0.04), MELD (p = 0.01) and CRP (p < 0.01). During a median follow-up of 16 months, 15.9 % had a liver transplantation (OLT) and 44 % patients died. The rate of OLT (24 vs. 10 %; p = 0.04) and death (68 vs. 29 %, p < 0.01) was significantly higher in patients with SBP than in patients without. A rise of serum creatinine (p = 0.01), CRP (p = 0.04) and a decrease in serum sodium (p < 0.01) at day 2-7 after SBP diagnosis were predictors of a worse outcome.

Conclusion: Staphylococcus, Entercoccus, E.coli, Streptococcus, and Candida are the most common species found in patients with SBP, while in Vienna the prevalence of multi-drug resistant bacteria remains low. Risk factors for SBP include include low hemoglobin, high WBC and high bilirubin. After diagnosis of SBP creatinine, serum sodium and CRP should be closely monitored, since they represent indicators of a worse outcome. Background: According to current European AIDS Clinical Society (EACS) guidelines for the treatment of chonic hepatitis C in HIV/HCV coinfected patients, HCV-Genotype (GT) and rapid virologic response (RVR) exclusively determine therapy duration. The aim of our study was to investigate the impact of interleukin 28B rs12979860 SNP (IL28B) and advanced liver fibrosis on the association between treatment duration and sustained virologic response Methods: 327 HIV/HCV coinfected patients who received antiviral therapy with pegylated interferon plus ribavirin (PEGIFN+RBV) were included in this multinational, retrospective study. Advanced liver fibrosis was defined as either METAVIR F3/F4 or liver stiffness > 9.5 kPa.

Results: Among HCVGT1/4 patients without RVR (HCVGT1/4-noRVR), a trend toward higher SVR rates (59 %) in patients with extended treatment duration (60-84) compared to patients treated for 36-60 weeks (40 %) was observed (p = 0.055), regardless of IL28B (IL28B C/C: 75 vs. 48 %, p = 0.117; IL28B non-C/C: 52 vs. 33 %, p = 0.132). While SVR rates were comparable between HCV1/4-noRVR patients without advanced liver fibrosis treated for 36-60 and 60-84 weeks (51 vs. 62 %, p = 0.432), significantly lower SVR rates were observed in patients with advanced liver fibrosis (12 vs. 46 %, p = 0.022). Patients with HCVGT2/3, RVR (GT2/3-RVR), and shortened treatment duration (12-36 weeks) displayed high rates of SVR ranging from 80 to 100 %, regardless of IL28B and advanced liver fibrosis.

Conclusion: Our study supports the recommended extension of therapy duration to 72 weeks for HIV/HCV coinfected patients with GT1/4-noRVR, regardless of IL28B. Especially GT1/4-noRVR patients with advanced liver fibrosis benefit from 72 weeks of treatment. In patients with GT2/3-RVR, the shortening of treatment duration to 24 weeks is associated with excellent SVR rates, regardless of IL28B and advanced liver fibrosis. Background: Interleukin 28B rs12979860 single nucleotide polymorphism (IL28B) is a major predictor of virologic response in both HCV monoinfected and HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin (PEGIFN+RBV). However, the impact of IL28B on the association between treatment duration and sustained virologic response (SVR) in HIV/HCV coinfected patients has yet to be examined.

Methods: 327 HIV/HCV coinfected patients treated with PEGIFN+RBV were included in this multinational, retrospective study and divided into groups according to their treatment duration (12-36 vs. 36-60 vs. 60-84 weeks). Extended treatment duration was defined as a treatment of at least 12 weeks longer than recommended by the 2011 European AIDS Clinical Society (EACS) guidelines.

Results: Patient characteristics: 81 % male, age: 40.9 ± 7.6 years, concomitant antiretroviral therapy: 82 %, baseline CD4 + T-lymphocyte count: 534 ± 251 cells/µl, treatment duration: 41.6 ± 16.2 weeks, HCV-GT1/4: 68 %, advanced liver fibrosis: 42 %, IL28B non-C/C: 57 %, RVR: 34 %, SVR: 53 %. In patients with IL28B non-C/C, SVR rates were significantly lower in patients treated for 12-36 (28 %), than in patients treated for 36-60 (53 %) and 60-84 weeks (55 %) (p = 0.003). In contrast, in patients with IL28B C/C, SVR rates did not vary significantly throughout the treatment duration groups (12-36:62 % vs. 36-60: 69 % vs. 60-84 weeks: 75 %, p = 0.574). While extended treatment duration was related to higher SVR rates (r = 0.176, p = 0.019) in patients with IL28B non-C/C, in patients with IL28B C/C, this correlation did not attain statistical significance (p = 0.075).

The association between treatment duration and SVR is influenced by IL28B. Nevertheless, decisions on treatment duration should primarily be based on HCV-GT and RVR, whereas IL28B may be considered as an additional factor for guiding individual treatment durations. Background: Both absolute CD4+ T-lymphocyte (CD4) count and CD4 percentage expressed as a proportion of lymphocytes are used as predictors of disease progression in HIV infected, as well as HIV/HCV coinfected patients. The aim of our study was to investigate the association between portal pressure and discordance between absolute CD4 count and CD4 percentage.

Methods: 97 HIV/HCV coinfected patients with compensated liver disease were included in this retrospective study. Portal pressure was measured by hepatic venous pressure gradient (HVPG). CD4 counts were considered as concordant when the absolute CD4 cell count matches the corresponding CD4 percentage determined in HIV infected individuals (absolute CD4 count/CD4 percentage: < 100/< 7 %, 100-199/7-13 %, 200-299/14-20 %, 300-399/21-27 %, 400-499/28-34 %, > 500/> 35 %). Higher CD4 percentages than expected from the absolute CD4 counts were referred to as high discordance while lower CD4 percentages than expected from the absolute CD4 count were referred to as low discordance.

Results: Patient characteristics: mean absolute CD4 count:519 ± 261cells/μl, mean CD4 percentage:28.6 ± 10.4 %, mean HVPG:4.8 ± 3.8 mmHg, cirrhosis:19 % of patients. High and low CD4 discordance was observed in 18 and 38 % of patients, while 44 % of patients had concordant CD4 counts. There was a tendency toward a higher prevalence of high CD4 discordance in patients with high portal pressure (≤ 5 mmHg: 15 vs.5-10 mmHg: 22 vs. ≤ 11 mmHg: 29 %, p = 0.651). In contrast, low CD4 concordance was observed more frequently in patients with low portal pressure (≤ 5 mmHg: 42 % vs. 5-10 mmHg: 39 % vs. ≤ 11 mmHg: 0 %, p = 0.109). Portal pressure was significantly correlated to the absolute CD4 count/ CD4 percentage ratio (r = − 0.201, p = 0.049).

Conclusion: In HIV/HCV coinfected patients, the relationship between absolute CD4 count and CD4 percentage is influenced by portal pressure, which might be attributed to hypersplenism in patients with portal hypertension.

Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention Dabigatran is an oral thrombin inhibitor, approved in several countries for prevention of stroke/embolism in atrial fibrillation as an alternative to vitamin-K-antagonists (VKA) although important issues have not been clarified, as illustrated by the following case.

Case report: An 85-year old man with gross hematuria had a history of hypertension, atrial fibrillation, chronic obstructive pulmonary disease, renal failure, metastatic prostate cancer and nondisabling stroke. Despite well-controlled VKA-therapy, two further non-disabling ischemic strokes occurred, and anticoagulation therapy was switched from phenprocoumon to dabigatran assuming that dabigatran would be indicated in a case of "VKA-failure". Since the glomerular filtration rate was 38 ml/min/1.73 m 2 dabigatran 110 mg/bid was prescribed.

Following antibiotic therapy of an urinary tract infection, the patient suffered from diarrhea and loperamide 2 mg bid for two days was prescribed. Two days later gross hematuria started. Dabigatran was stopped after the patient had taken the last dose in the morning of day 1. Hematuria persisted, necessitating 2 blood transfusions. On cystoscopy no bleeding source was identified. The thrombin time was 75 s even 31 h after intake of the last dabigatran dose. To stop bleeding, 4 units of fresh frozen plasma were given. On day 3, hematuria ceased and eventually the patient was discharged with enoxaparin-therapy.

Conclusion: Dabigatran in patients with carcinoma and P-gpaffecting drugs may cause major bleeding. There is a need for monitoring tools of the anticoagulant status of patients receiving dabigatran in bleeding situations, an antidote and research about drug-drug interactions and urological side effects.

Renal function, P-glycoprotein-affecting drugs and stroke prevention in atrial fibrillation patients C. Stöllberger, F. Höllerl, J. Finsterer

Background: Dabigatran is an oral thrombininhibitor which showed similar efficacy as warfarin for stroke prevention yet a lower bleeding rate in patients with atrial fibrillation (AF) in the RE-LY study. The serum concentration of dabigatran is influenced by renal function as well as the P-glycoprotein-(P-gp)-system. The aim of this cross-sectional study was to assess renal function and prescription frequency of P-gp-affecting drugs in hospitalized AF patients.

Methods: P-gp-affecting drugs were searched from the literature. Consecutive patients with AF hospitalized between December 2009 and January 2010 were included. The CHADS 2 score was assessed, the medication was registered and screened for P-gp-affecting drugs. The glomerular filtration rate (GFR) was calculated by the "modification of diet in renal disease" formula.

Results: In 100 patients (47 females, mean age 74 ± 12 year), the mean CHADS 2 score was 2.4 ± 1.4. GFR was < 30 ml/min/1.73 m 2 in 9 patients, 30-45 in 12 patients, 46-59 in 21 patients, 60-89 in 42 patients and ≥ 90 ml/min/1.73 m 2 in 16 patients. Forty-two patients took at least one, and 4 patients two P-gp-affecting drugs: Simvastatin (n = 22), amiodarone (n = 8), vitamin E (n = 8), carvedilol (n = 4), diltiazem (n = 2), dipyridamole (n = 1), propranolol (n = 1), verapamil (n = 1). P-gp-affecting drugs were prescribed to 3 patients with GFR < 30 ml/min/1.73 m 2 , 4 patients with GFR 30-45, 9 patients with GFR 60-89, 18 patients with GFR 60-89 and 7 patients with GFR ³ 90.

Only 9 patients had a normal renal function as well as no prescription of P-gp-affecting drugs.

Conclusion: Normal renal function was present in only 16 % of hospitalized AF-patients. P-gp-affecting drugs were prescribed to 42 % of hospitalized AF patients. Only 9 % of hospitalized AF patients have a normal renal function and do not receive P-gp-affecting drugs. More information about the relevance of impaired renal function and druginteractions is warranted before dabigatran may be widely used for stroke prevention. Methods: In this prospective, longitudinal study, sP-selectin, D-dimer and hs-CRP were determined by enzyme-linked immunosorbent assay, quantitative latex assay and particle enhanced immunonephelometry, respectively, in 44 patients with sonographically confirmed acute DVT at the time of diagnosis, and one, three, six and 12 months later. SP-selectin and hs-CRP were also measured in 88 age-and sex-matched healthy controls. Further, color duplex sonography was performed in all patients at each time point.

Results: At DVT diagnosis, sP-selectin and hs-CRP were significantly higher in patients compared to healthy controls. From baseline to one month, both parameters decreased significantly. In patients with oral anticoagulation (OAC) for six months (n = 35) levels of sP-selectin increased significantly after cessation of anticoagulant therapy (p = 0.002), while sP-selectin was similar to healthy controls in patients with ongoing OAC (n = 9) at 12 months (p = 0.49). In contrast, hs-CRP in both subgroups remained constantly low at levels seen in healthy controls. The course of D-dimer was similar to sP-selectin. Color duplex sonography showed no ongoing thrombus formation in any patient. 34 (77.3 %), 29 (65.9 %), 26 (59.1 %) and 25 (56.8 %) patients had residual thrombosis one, three, six and 12 months after the acute event, respectively. Levels of D-dimer and sP-selectin did not differ significantly between patients without and with residual thrombosis.

Conclusion: Concentrations of sP-selectin and D-dimer after acute DVT seem to be strongly influenced by treatment with vitamin K antagonists. After withdrawal of oral anticoagulation, they rise again and could therefore reflect a prothrombotic state, which is susceptible to pharmacologic therapy. The functional polymorphism of erythropoietin gene rs1617640 G > T is not associated with susceptibility and clinical outcome of early-stage breast cancer Background: The purpose of pharmacogenetics is to elucidate the role of predictive factors on individual's drug response based on genetic variation. We examined the association between germline polymorphisms in genes involved in the protection against oxidative stress, apoptosis, oncogenic transformation, proliferation, immune response and DNA repair and the pathological response to anthracycline-based neoadjuvant chemotherapy in patients with breast cancer.

Methods: The DNA was genotyped for 8 polymorphisms in 5 genes (TP53, NQO1, IL6, TLR4 and XRCC1) in 70 breast cancer patients by 5'-exonuclease (TaqMan ™) technology. Fisher's exact test was used to evaluate the association between the genotype, clinicopathological parameters and pathological response.

Results: A good pathological response, defined as a pathological complete response or residual isolated invasive tumor cells, was found significantly more frequently for estrogen (ER) and progesterone receptor (PR) negative breast carcinomas compared to ER and PR positive and ER or PR positive carcinomas, respectively (43.5 versus 37.5 and 10.3 %, p = 0.006), and was significantly associated with high tumor grade (G3) (p = 0.002). A non-significant trend towards a good pathological response was shown in patients carrying the Arg/Arg or Arg/Pro TP53 codon 72 gene variant compared to those harbouring the Pro/Pro variant (17.6 or 37.9 % versus 0; p = 0.071). No association was found between NQO1 Pro187Ser, IL6 -174G > C, TLR4 Asp299Gly and Thr399Ile, and XRCC1 Arg194Trp, Arg399Gln and Arg280His and pathological response.

Conclusion: The present study shows hormone receptor status and tumor grade as predictors for pathological response to neoadjuvant anthracycline-based chemotherapy. Among various functional germline polymorphisms a potential predictive value was only found for the TP53 Arg72Pro gene variant.

Fatal Enterococcus feacalis septicaemia and Enterococcus faecium mitral valve endocarditis after spondylodiscitis under dabigatran for stroke prevention C. Stöllberger, El. Bonner, J. Finsterer

Background: Dabigatran is an oral thrombin inhibitor for prevention of stroke or embolism in atrial fibrillation (AF)-patients as an alternative to vitamin-K-antagonists (VKAs). Thrombin plays also a role in infection and sepsis. The fatal course of a patient with sepsis, 7 weeks after initiation of Dabigatran is reported.

Case report: A 74 years old female had a long-standing history of hypertension, AF, osteoporosis, lumbar pain, mitral insufficiency, and a recent 4-months hospitalization because of suspected Staphylococcus aureus-spondylodiscitis L5/S1, Klebsiella urinary tract infections, Clostridium difficile enteritis, heart failure, and acute renal failure. Since monitoring of INR-values because of VKA therapy was estimated as too cumbersome dabigatran was started. At hospital-discharge, the glomerular filtration rate (GFR) was 52 ml/min/1.73 m 2 , and her medication consisted of pantoprazole, nebivolol, mirtazapine, spironolactone, sertraline, torasemide, pancreatin, dabigatran and amiodarone. She did not visit a physician after discharge. She was admitted 7 weeks later because of generalized weakness with a GFR of 22 ml/min/1.73 m 2 . Because of hypotension, haematemesis and melaena, she was admitted to the intensive care unit, received catecholamines, continuous haemofiltration, and was intubated and mechanically ventilated. In the blood cultures grew Enterococcus faecalis why meropenem was started. She died 65 h after admission. Autopsy revealed mitral leaflet-vegetations and pyelonephritic abscesses. Candida albicans, Bacteroides fragilis and Enterococcus faecium grew on the mitral leaflet-vegetations and Candida albicans and Enterococcus faecium on the renal abscesses. Background: Diagnosis of acute coronary syndrome (ACS) is based on clinical symptoms, findings of electrocardiogram and cardiac biomarkers as reflected by cardiac troponin. Emerging biomarkers such as copeptin may be helpful in early diagnosis and risk stratification in patients with ACS.

Methods: In this evaluation study we measured 155 samples of patients with ACS admitted to the coronary care unit. Copeptin was determined using an automated immunofluorescent assay on a Kryptor instrument (B•R•A•H•M•S GmbH, Hennigsdorf, Germany). Levels of high-sensitivity troponin T (hsTnT) were measured with an electrochemiluminescence immunoassay on an Elecsys system (Roche Diagnostics, Mannheim, Germany).

Results: One hundred and thirteen male and forty two female patients with a mean age of 64 ± 13 years presented with chest pain. Of these, 100 patients (64 %) were classified as having a ST-elevation myocardial infarction (STEMI), 51 (33 %) a non-ST-elevation MI (NSTEMI) and 4 (3 %) an unstable angina pectoris (UAP). Copeptin levels were higher in UAP patients compared to those having STEMI and NSTEMI (median 48.6 pmol/L vs 25.2 pmol/L vs 19.8 pmol/L). Thirteen patients had hsTnT levels between 14 and 50 pg/mL. Of interest, 9 of these 13 patients had copeptin levels above the cutoff point whereas in 4 out of 13 patients copeptin levels were within the normal range (blood sampling 1 h and 2-6 days after onset of chest pain in 1 patient and 3 patients, respectively).

The results of our study suggest an additional diagnostic value of copeptin measurements in patients with hsTnT levels below 50 pg/mL. However, the clinical value of copeptin in the management of ACS should be further evaluated. Pyruvate dehydrogense kinase isoforms inhibit pyruvate dehydrogenase, which constitutes an important step in glucose metabolism. It is involved in various phenomena of aging and its expression changes with age, which is generally not well understood as yet. Cardiac metabolism of glucose is very tightly controlled in order to maintain the variable energy demand that is required by cardiac tissue. Energy metabolism of the cardiac myocyte can be regulated within seconds up to a few minutes or chronically regulated within the time frame of hours to days. Glucose metabolism is activated in early myocardial ischemia and in response to an increased need of high-energy-phosphate in the healthy heart during extreme physical activity. In myocardial ischemia, inhibition of PDK expression would be beneficial in order to shift myocardial metabolism from adult towards the fetal phenotype, thus metabolising more glucose than fat in order to preserve myocardial integrity.

Myocardial tissue probes derive from the right auricle of patients undergoing cardiac surgery. A small part of the right auricle is removed when the heart is put on extra-corporal circulation. This sample is then be placed in cooled Tyrode solution and hypoxia is brought about by switching 100 % oxygen to 100 % nitrogen (hypoxia) in one of the two chambers. By doing so, we are able to compare ischemic and non-ischemic tissue of the same patient. Snap frozen samples are stored at − 70° C until RNA isolation. Quality of isolated RNA is analysed by Agilent's Bioanalyzer 2100 system. Arrays are scanned with the AB1700 Chemiluminescence Array Reader and images, data are processed by PANTHER software.

In our microarray experiments, we find that, in particular, PDK isoform 4 is significantly less expressed under nebivolol both during O2 perfusion and simulated ischemia, an effect practically negligible under atenolol. Here, nebivolol also exhibits a unique cardioprotective property, different from standard β-blockers.

We find that, without the influence of beta-blockers, there is no significant regulation of PDK-expression during myocardial ischemia. There is just a trend towards a decrease in PDK-Gene expression. There is, however a significant difference between the expression of PDK during myocardial ischemia in the presence of atenolol (3.62 ± 0,18) and nebivolol (1.97 ± 0.06; ± SEM; P ≤ 0.05): PDK-expression is decreased during normoxia (trend) and ischemia (significant) in the presence of nebivolol.

Here, confirmed by real time PCR, the finding that PDK gene expression is down-regulated by nebivolol compared to atenolol in normoxia (trend, not statistically significant) and simulated ischemia/hypoxia (statistically significant) may argue for a higher protective, anti-ischemic but also anti-anginal metabolic potential of nebivolol compared to standard β-blockers like atenolol. Especially patients with angina may profit from this particular property of nebivolol over atenolol. 

Background: Cardiopulmonary bypass, utilized in on-pump coronary artery bypass graft procedure (CABG) is known to affect cytokine release leading to a generalized endogenous immune sup-pression. We investigated whether continued ventilation on cardiopulmonary bypass induces attenuation of immune response.

Methods: 30 patients undergoing conventional coronary artery bypass graft (CABG) operation were randomized into a ventilated on CPB (VG; n = 15) and non-ventilated (NVG; n = 15) CPB group. Blood samples were drawn at the beginning and end of surgery, and the five consecutive days. sST2, IL-4, IL-10, IgM, IgG, IL-6 and endotoxin were measured by ELISA. Data are given as mean ± standard error of the mean (SEM). An unpaired t-test or Mann-Whitney-Utest was used for statistical analysis.

Results: Serum levels of sST2 and IL-10 were significantly higher in the CABG NVG as compared to VG within 24 h after operation (sST levels at day 1: VG vs. NVG; 1366.4 ± 111.9, 2296.3 ± 463.6; p = 0.033). In addition, also the pro-inflammatory IL-6 secretion was significantly reduced in the VG. Moreover, sST2 secretion correlated with systemic endotoxin levels (24 h post CABG, R = 0.423, p < 0.020). IL-4, IgM and IgG were not altered between the two study groups.

Conclusion: Continued mechanical ventilation during CABG results in a significant reduction of sST2, IL-10 and IL-6 levels within 24 h after CABG surgery. This data suggests that continued mechanical ventilation during CABG attenuates inflammatory and anti-inflammatory immune response after CPB. With regard to the underlying mechanisms, further studies are necessary to fully understand the mode of action of continued ventilation; however we strongly believe that our present study can serve as a good basis for such a study in the future.

Background: Cardiopulmonary bypass, utilized in on-pump coronary artery bypass graft procedures (CABG) induces generalized immune suppression and release of heat shock proteins(HSP), cc-CK18 and mononuclear cell activation markers. We hypothesized that continued ventilation on cardiopulmonary bypass (CPB) induces attenuation of immune response.

Methods: 30 patients undergoing conventional coronary artery bypass graft (CABG) operation were randomized into a ventilated on CPB (VG; n = 15) and non-ventilated (NVG; n = 15) CPB group. Blood samples were drawn at the beginning and end of surgery, and the five consecutive days. HSP27, HSP60, HSP70, MIP-1 beta, MIP-3alpha, MCP-1, and cc-CK18 were measured by ELISA. Data are given as mean ± standard error of the mean (SEM). An unpaired t-test or Mann-Whitney-U-test was used for statistical analysis.

Results: Serum levels of HSP70 were significantly lower in VG compared to NVG 24 h after CABG procedure (1629.2 ± 157.1 vs. 5203.5 ± 549.6 pg/ml, p < 0.001). The mean MIP-1beta levels measured at day 1, day 2 and day 3 after CABG surgery were significantly lower in the VG compared to the NVG (p < 0.01). Moreover MCP-1 P53 P54 abstracts 43. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin 579 ÖGIM 1 3 concentrations were significantly reduced in the VG compared to the NVG at day 3, day 4 and day 5 (p < 0.05). HSP27, HSP-60, MIP-3alpha and cc-CK18 concentrations showed now differences between the two groups.

Conclusion: Significantly less HSP70 was detectable in patients receiving uninterrupted lung ventilation on CPB, possibly indicating a difference in inflammatory responses, cellular stress or damage between the ventilated and non-ventilated group. In addition selected inflammatory markers were slightly reduced in the VG. These date suggest that inter-operative ventilation has a protective effect on HSP70 secretion in CABG patients.

New NO-donor S-NO-HSA is a promising preclinical treatment approach for myocardial infarction Background: We evaluated the influence of an application of the new NO-donor S-NO-HSA on the hemodynamic function of infarcted rat hearts, in order to tackle ischemia/reperfusion injury after reopening the occluded vessel.

Methods: 26 male Sprague Dawley rats underwent 60' LAD ligature followed by 120' in vivo reperfusion. 15' after LAD occlusion 0.27 μmol/kg/h S-NO-HSA were randomly applied to 12 rats (control: n = 14; treatment: n = 12) intravenously for 75 min. Afterwards, hearts were quickly excised and hemodynamic evaluation was performed in an erythrocyte perfused isolated working heart for 45' (control: n = 10, treatment: n = 8) or TTC and Evans Blue Staining was performed in vivo (control: n = 4, treatment: n = 4) to determine left ventricular (LV) infarct size (IS%LV) and area at risk (AAR%LV).

Results: Staining revealed equal IS (control: 39.07 ± 3.20 % vs. treatment: 38.08 ± 2.12 % n.s.) while AAR was significantly smaller after S-NO-HSA treatment (control: 79.36 ± 7.35 % vs. treatment: 55.09 ± 3.39 % p ≤ 0.05). Also, working-heart evaluation revealed significantly better hemodynamic function in the NO treatment group: External Heart Work (control: 4745 ± 302 mL/min × g vs. treatment: 6262 ± 548 mL/min × g p ≤ 0.05), Cardiac Output (control: 22.96 ± 1.37 mL/min vs. treatment: 33.21 ± 2.16 mL/min p ≤ 0.01). There was no significant difference in coronary flow (control: 1.87 ± 0.15 mL/min vs. treatment: 1.91 ± 0.13 mL/min n.s.). Blood gas analyses showed equal myocardial oxygen delivery in both groups (control: 24.31 ± 1.98 mL/min × g vs. treatment: 28.59 ± 1.49 mL/ min × g n.s.) however myocardial oxygen uptake was significantly higher in the treatment group (control: 5.60 ± 0.21 mL/min × g vs. treatment: 8.21 ± 0.42 mL/min × g p ≤ 0.01).

Conclusion: S-NO-HSA significantly improves hemodynamic function after ischemia/reperfusion. In fact, it prevents endothelial dysfunction and thereby reduces AAR. We believe that S-NO-HSA might be an interesting therapeutic option for patients with myocardial infarction and interventional revascularization.

Background: The antiplatelet effect of clopidogrel is subject to considerable inter-individual variations. In vitro high on-treatment residual platelet reactivity (HRPR) has been linked to cytochrome P450 (CYP) 2C19*2 carriage, and both were significantly associated with the occurrence of adverse events after coronary stenting. It has been shown that besides CYP2C19, CYP2C9 is involved in the hepatic biotransformation of clopidogrel to its active metabolite. Consequently, CYP2C9 polymorphisms may also affect the extent of clopidogrel-mediated platelet inhibition. We therefore studied the influence of CYP2C9 allelic variants on clopidogrel-mediated platelet inhibition as assessed by 5 platelet function tests.

Methods: On-clopidogrel residual platelet reactivity was assessed by light transmission aggregometry (LTA), the VerifyNow P2Y12 assay, the VASP assay, multiple electrode aggregometry (MEA), and the Impact-R in 288 patients after angioplasty and stenting for cardiovascular disease. Allelic variants CYP2C9*2 and *3 were determined using a RealTime PCR assay.

Results: A significantly higher on-treatment platelet reactivity was found for patients with loss-of-function (LOF) status (wt/*3, *2/*2, *3/*3) compared to normal-function genotype (wt/wt, wt/*2) using the VerifyNow assay (P = 0.01). An in trend increase was seen with LTA (P = 0.06) while results did not differ for the VASP assay, MEA or the Impact-R. Further, in univariate and multivariable logistic regression analysis the LOF genotype was associated with HRPR determined by the VerifyNow P2Y12 assay (P = 0.02) but not by any other assay.

Conclusion: Results from the VerifyNow P2Y12 assay are significantly influenced by CYP2C9 LOF variants leading to decreased clopidogrel-mediated platelet inhibition and an increased rate of HRPR. Research of the last two decades tells us that β-blockers not only are excellent antihypertensive drugs but also successfully counteract deleterious spirals in CHF and ischemia. Recent data have suggested in this context that the return of AGATM expression from its elevated level to normal during recovery from ischemia may be a consequence of β -blocker therapy. Here, we look at the expression of AGATM in experimentally normoxic and hypoxic human myocardial tissue derived from cardiac surgery the presence and absence of β-blockers in vivo. In microarray preliminary (Table 1) Using real-time PCR, we could confirm the above data: We found that, without the influence of betablockers, there is no significant regulation of AGATM-expression during myocardial ischemia. There was, however, a significant difference between the expression of AGATM during myocardial ischemia in the presence of atenolol (1.546 ± 0.05) and nebivolol (1.10 ± 0.04; ± SEM; P ≤ 0.05). As to myocardial ischemia, O 2 -consumption correlates with the amount of cytoplasmic creatine available. The synthesis of high energy phosphate and thus oxygen consumption will be decreased in myocardial tissue prone to a lesser creatine synthesis. Thus, down-regulation of myocardial AGATM by ß-blockers may partially explain cardioprotective effects of β-blockers and help to reduce cardiovascular events in hypertensive patients at risk for ischemic heart disease an CHF. Background: Myotonic dystrophy 1 (MD1) is an autosomal dominant disorder that is regarded as the most common muscular dystrophy in adults. Patients with MD1 are at high risk for arrhythmias and sudden death due to conduction defects as well as ventricular arrhythmias. Implantable cardioverters (ICD) and antibradycardic pacemakers (PM) are effective to prevent fatal outcomes of arrhythmias, and the proper selection of patients is crucial. Implantable loop-recorders (ILR) are developed to detect arrhythmias. Aim of the study was to present our experience with ILR in patients with MD1.

Methods: Included were all patients with MD1 who underwent implantation of an ILR in the Krankenanstalt Rudolfstiftung starting in January 2005 until March 2012. Clinical cardiologic, electrocardiographic and neurological characteristics as well as events during follow-up and consequences of ILR interrogations were registered.

Results: Seven patients with MD1, aged 34-64 years, with inconclusive findings on 24-hour-Holter recording were included. Implantable loop-recorders detected arrhythmias which resulted in implantation of pacemakers in three and of cardioverter/defibrillator in one patient.

Conclusion: We conclude that implantable loop-recorders are useful in detecting arrhythmias in MD1 patients.

Experimental evidence suggests a crucial role of immune reaction in the pathophysiology of atherosclerosis and acute myocardial infarction. For example, a few regulatory T-cells control a wide spectrum of the inflammatory cascade. In ischemia, a pro-inflammatory imbalance with damaging effects in terms of left ventricular performance and patient outcome is the result of this uncontrolled immune response (Am Heart J 2008; 156:1065 -1073 . Ischemic injury leads to left ventricular remodelling and oxidative stress and inflammation are key elements in this context. Leukocyte-derived markers such as myeloperoxidase (MPO) correlates with outcome in ischemic heart disease.

In our present work using microarray technique, we have found that, in T-cell mediated immunity generally, a noteworthy downregulation is brought about by β-blockers. From our investigations we suspect that most important, unique pleiotropic effects of P58 P59 P60 abstracts 43. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin 581 ÖGIM nebivolol may be centered around favourable effects upon T-cell mediated response to ischemia. In our microarray experiments we found an up-regulation of MPO expression in the presence of nebivolol as well as in the presence of atenolol both in hypoxic as well as in well oxygenated conditions, as can be seen below. Using PCR for validation, we find that during experimental ischemia, there is an up-regulation of MPO-expression. There is a differential regulation between different beta-blockers during myocardial ischemia, which warrant further investigation. Using PCR for validation, we find that during experimental ischemia, there is an up-regulation of MPO-expression. There is a differential regulation between different beta-blockers during myocardial ischemia, which warrant further investigation. We believe that there are complex pleiotropic effects of β-blockers on immunity. Such pleiotropic effects have received more attention recently. For example, in the JUPITER trial, in apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events by unfolding pleiotropic anti-inflammatory actions. (JUPITER Study N Engl J Med. 2008 Nov). Our preliminary results show that β-blockers inhibit the expression of T-cell immunity related genes during experimental hypoxia and we find that during experimental ischemia, there is an up-regulation of MPO-expression. There is a differential regulation between different beta-blockers during myocardial ischemia, which warrant further investigation. In the light of JUPITER and other recent publications on modulating inflammation by pleiotropic effects of cardiovascular drugs, the specific property of immune modulation by β-blockers in myocardial ischemia may warrant further attention. However, a further detailed exploration on both expression and molecular level is certainly needed. Fallbericht: Ein 47jähriger Patient wird wg. hochfieberhaftem Zustandsbild und Kollapsgeschehen aufgenommen. Bislang gesund, in der Anamnese Z. n. 3 Zeckenbissen 14 Tage zuvor an der linken Axilla. An der Bissstelle hatte sich innerhalb der letzten 3 Tage ein deutliches Erythem gebildet. Bei Aufnahme hat der Pat. bis auf allg. Krankheitsgefühl keine Beschwerden.

Klinisch und laborchemisch besteht eine Infektion mit Myokardbeteiligung bei erhöhtem hsTNT von 121 ng/l (Normwert bis 14 ng/l), sowie CK von 223 U/l (Normwert bis 190 U/l) und Erre-gungsrückbildungsstörungen im EKG, differentialdiagnostisch muss an ein akutes Koronarsyndrom i. R. eines Infekts gedacht werden.

Bei V.a. akute Borrelienkarditis Beginn einer Antibiose mit Ceftriaxon.

Aufgrund der EKG Dynamik mit steigenden Troponinwerten und neu aufgetretener AP Symptomatik erfolgt eine Koronarangiographie mit blandem Befund.

Eine initial echokardiographisch festgestellte Wandbewegungsstörung ist im Verlauf nicht mehr nachweisbar.

Serologisch kann bei Nachweis von positiven IgM und neg. IgG eine frische Borrelieninfektion diagnostiziert werden.

Aufgrund des guten klinischen Ansprechens unter Ceftriaxon als auch Rückgang der Herzenzyme erfolgt keine Myokardbiopsie. Im gesamten Verlauf konnten keine Rhythmusstörungen detektiert werden.

Schlussfolgerung: Eine kardiale Beteiligung wird bei der Lyme-Borreliose in ca. 4-10 % beobachtet. Zu den häufigsten Frühmanifestationen der akuten Lyme-Karditis zählen Reizleitungsstörungen sowie eine Perimyokarditis. Beschrieben wird die Lymekarditis meist im Stadium II der Borreliose.

Wenige erforscht ist noch wie häufig im Rahmen einer akuten Bakteriämie bereits eine Myokardbeteiligung auftritt, die zu einer chron. Verlaufsform mit Reizleitungsstörungen und Kardiomyopathie führen kann. Ein 36-jähriger Patient wurde zur Abklärung einer kürzlich erstdiagnostizierten hypertrophen Kardiomyopathie (CMP) vorgestellt. An Vorerkrankungen konnte eine bilaterale Innenohrschwerhörigkeit mit Hörgerätversorgung seit dem 24. Lebensjahr, ein relativer Kleinwuchs sowie ein insulinpflichtiger Diabetes mellitus (DM) (ED mit 21 Jahren) erfasst werden. Weiters bestand eine okuläre Apraxie, eine mehrmals wöchentlich auftretende Cephalea sowie Z.n. fraglicher TIA. Klinisch fand sich kein Hinweis auf eine Myopathie. Die Mutter des Patienten verstarb relativ jung an einem Schlaganfall, ein Bruder des Patienten hat ebenfalls einen insulinpflichtigen DM.

Echokardiographisch zeigte sich eine asymmetrische linksventrikuläre Hypertrophie ohne nachweisbare intracavitäre Obstruktion. Die systolische LVF war deutlich eingeschränkt. In der Koronarangiographie fand sich eine wirksame Stenose eines diagonalen Astes, die Füllungsdrücke waren normal. Eine kardiale Amyloidose konnte ebenso wie ein M. Fabry ausgeschlossen werden.

Die Befundkonstellation -CMP, insulinpflichtiger DM, okuläre Apraxie, relativer Kleinwuchs, erhöhtes Laktat im Serum und Laktatpeaks in der cerebralen MRT Spektroskopie -waren hinweisend auf eine Mitochondriopathie. Die histopathologische Aufarbeitung der Endomyokardbiopsie unterstützte diese Vermutung. Die molekulargenetische Mutationsanalyse, der aus dem Herzmuskelgewebe gewonnenen mitochondrialen DNA, ergab eine Mutation im Gen der t-RNA für Leucin (MTTL1-Gen), m.3243A > G. Diese Mutation ist in Zusammenhang mit verschiedenen syndromalen und P61 P62 abstracts ÖGIM nicht syndromalen Mitochondriopathien (insbesondere MELAS, Mitochondrial Encephalomyopathy, Lactic acidosis, Stroke like episodes) beschrieben. Da die diagnostischen Kriterien für ein MELAS Syndrom nur teilweise erfüllt waren, wurde die Diagnose einer Mitochondriopathie mit CMP, Schwerhörigkeit, DM und okulärer Apraxie gestellt.

Eine ursächliche Therapie für diese Erkrankung ist derzeit nicht verfügbar. Die Gabe bestimmter Medikamente ist kontraindiziert, bzw. sollte nur unter entsprechenden Vorsichtsmaßnahmen erfolgen. Der Patient ist nach Verbesserung der LV-Funktion unter neurohumoraler Therapie dzt. in einem klinisch stabilen Zustand. Background: Hereditary amyloidosis with consecutive renal disease is an autosomal-dominant disorder that can be caused by mutations in the gene encoding the fibrinogen Aα-chain. Here we describe the detailed clinical course of amyloidosis due to the R554L mutation, and further assess the presence of extrarenal amyloid deposits, and their possible influence on cardiovascular morbidity.

Methods: We report on a large Spanish family that includes 101 members. We conducted patient interviews, chart review, genetic testing, renal biopsies, and an intensive search for extrarenal amyloid disposition.

Results: Two living and 8 deceased family members had chronic kidney disease, with late-onset gross proteinuria and a variable course of declining renal function, starting in their early fourth decade of life. In both affected living members, we identified the fibrinogen R554L mutation. Renal biopsies from two affected members revealed almost complete obliteration of the mesangial glomerular architecture, although kidney function was only moderately impaired. Neither extrarenal involvement by amyloid nor accelerated arteriosclerosis was evident. Two deceased siblings of this family had undergone kidney transplantation with the longest graft survival of 13 years.

Conclusion: In the reported family, amyloid deposition specifically affected the kidneys and was not associated with accelerated atherosclerosis. The clinical picture caused by the R554L fibrinogen Aα chain variant is similar to that associated with the more prevalent E526V mutation. In the ongoing controversy whether specific forms of amyloidosis may be restricted to the kidneys, our data support the position that these rare fibrinogen mutations lead to a unique disease entity that is not accompanied by generalized vascular amyloid disposition. Background: Hypertonic citrate (46.7 %) instilled into catheters inevitably spills into the systemic circulation in exchange for blood entering the catheter and diluting the concentration of the lock solution. This process is driven by different densities of whole blood and lock solution. Hence, in a vertical catheter, intra-luminal citrate concentration ranges from 0 (at the tip in catheters with sideholes), 3 % (between the sideholes and the relativ highest point of the catheter) to 46.7 % (at the luer end) with potential differences in antimicrobial effects. We in vitro investigated the antimicrobial efficacy of pure citrate 46.7 %, citrate 46.7 % diluted with whole blood (= citrate 3 %) and of whole blood without citrate, mimicking in vivo conditions in different catheter compartiments.

Methods: Time kill studies (in duplicate) measuring the antimicrobial effect up to 24 h exposure to citrate 46.7 %, citrate 3 % and whole blood without citrate on overnight cultures (5 ´ 10 8 cfu/ml) of E. coli and Staph. aureus were performed with each test solution.

Results: Citrate 46.7 % reduced E. coli (2 log units) but after 24 h 10 6 cfu/ml were still present. Whole blood diluted citrate 3 % and whole blood without citrate had no antimicrobial effect. Citrate 46.7 %, whole blood diluted citrate 3 % and whole blood had no antimicrobial effect on Staph. aureus within 24 h.

Conclusion: Spillage of catheter lock solution replaced by whole blood leading to reduced intra-luminal citrate concentration considerabely reduces the antimicrobial effect of citrate 46.7 % on E. coli. There was no antimicrobial effect on Staph. aureus with all solutions tested. Therefore, the antimicrobial efficacy of hypertonic citrate lock solution has to be seriously questioned. Furthermore, as dilution with whole blood alters antimicrobial activity in general, antimicrobial activity of a given lock solution needs to be tested in presence of whole blood.

Ethanol lock induced intraluminal plasma protein precipitation might cause occlusion of hemodialysis access devices treat or prevent catheter related infections. Following instillation of ethanol lock solution into the catheter the density difference between whole blood and ethanol causes gravity induced seepage of ethanol paralleled by a reverse whole blood influx into the catheter. Therefore, whole blood is exposed to highly concentrated ethanol, which is a common agent for protein precipitation. We aimed to investigate protein precipitation in ethanol locked catheters as a possible cause of catheter occlusion.

Methods: In vitro, blood plasma and ethanol (concentrations ranging from 7 to 70 %) mixtures in a ratio of 1:4, representing the intraluminal catheter conditions, were centrifuged at room temperature and 4000 r.p.m. for 10 min to visibly assess protein precipitation.

Results: Optically detectable protein precipitation was observed in test solutions containing ethanol lock solutions above a concentration of 30 %.

Conclusion: Our in vitro data suggest that observed occlusion of central venous catheters locked with ethanol might be due to intraluminal protein precipitation following exposure of plasma proteins to ethanol. Furthermore, injection or gravity induced leakage of precipitated protein particles into the pulmonary circulation may cause pulmonary embolism. We suggest that ethanol lock solution up to the concentration of 30 % can be used safely. Grundlagen: Metabolische Ursachen einer Rhabdomyolyse sind vergleichsweise selten. Wir berichten über einen jungen Mann, bei dem infolge einer unsubstituierten Hypothyreose eine schwere Rhabdomyolyse auftrat, die zu einem akuten dialysepflichtigen Nierenversagen führte.

Fallbericht: Ein 34-jähriger Patient wurde in reduziertem Allgemeinzustand ins Krankenhaus eingeliefert. Fünf Tage zuvor waren polytope Muskelschmerzen und dunkler Harn aufgefallen, die Harnmenge hatte ebenso abgenommen. Trauma oder Drogenkonsum wurden verneint. Im Labor zeigte sich ein Nierenversagen mit einem Kreatinin von 32,9 mg/dl sowie Elektrolytentgleisungen (K 8,9 mmol/l, Ca 1,78 mmol/l, Ph 5,53 mmol/l), zudem eine deutliche Erhöhung der Creatinkinase und erniedrigte Schilddrüsenwerte. Die Krankengeschichte deckt eine substitutionspflichtige Hypothyreose nach Thyreoidektomie auf, die Medikation wurde vom Patienten vor 1 Jahr abgesetzt. Der Patient wurde auf der Intensivstation hämofiltriert, Flüssigkeit wurde zugeführt und die Schilddrüsensubstitution wieder eingeleitet. In den folgenden Stunden kam es zu zwei generalisierten tonisch-klonischen Anfällen, welche als Ausdruck einer urämischen Enzephalopathie interpretiert und mit Levetiracetam therapiert wurden. Da sich für eine infektiöse, traumatische oder medikamentös induzierte Ursache der Rhabdomyolyse keine Hinweise fanden, ist diese am ehesten durch die manifeste Hypothyreose erklärlich. Nach 72 Stunden konnte die Hämofiltration beendet und der Patient auf die Normalstation verlegt werden. Die Polyurie zeigte sich zu diesem Zeitpunkt bereits rückläufig.

Schlussfolgerung: Der Ausschluss einer anderen Ursache und die Rückbildung der klinischen Symptomatik sowie die Besserung der Nierenfunktion sprechen für die Hypothyreose als Auslöser der Rhabdomyolyse. In seltenen Fällen führt sie, wie in unserem Fall, sogar zu einem dialysepflichtigen Nierenversagen. Bei unklarer Rhabdomyolyse sollten auf jeden Fall die Schilddrüsenparameter bestimmt werden.

Serum amyloid a in high-density lipoproteins induces inflammation in chronic kidney disease: Assessment as novel biomarker for cardiovascular diseases C. Kopecky 1 , C. Gerner 2 , P. Eller 3 , G. Zlabinger 4 , T. Weichhart 5 , M. Säemann 1 Background: Cardiovascular events are the main cause of death in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Individuals with renal dysfunction are further characterized by increased atherosclerosis and dyslipidemia affecting quantity and function of high density lipoproteins (HDL). The anti-inflammatory potency of HDL is impaired in patients, thus converting the molecule into a dysfunctional, pro-inflammatory particle. To determine the underlying molecular reasons, we used shotgun proteomics to identify disease-specific proteins in HDL of ESRD patients and define a characteristic HDL profile.

Methods: HDL was isolated from fresh human plasma by sequential ultracentrifugation and objected to proteomic analysis. HDL-associated proteins were identified by MS Analysis. Human monocytes were stimulated with HDL and SAA, SP-B or apo-CII. HDL-bound proteins were detected by enzyme-linked immunosorbent assay.

Results: We found that certain proteins, including surfactant protein B (SP-B), serum amyloid A (SAA) and apolipoprotein-CII (apo-CII) are significantly enriched in HDL of ESRD patients. Of these, SAA promotes inflammatory cytokine production and reverses the protective function of healthy HDL, suggesting a possible link to cardiovascular mortality in CKD and ESRD. Therefore, we established SAA levels in HDL as novel biomarker to predict individual cardiovascular consequences, disease progression and mortality. We developed an easy applicable assay using plasma samples for quantitative detection of HDL-bound SAA. Our assay exclusively captures HDL without the requirement of a preliminary, extensive isolation of HDL and can also be subjected to detect other HDLassociated proteins.

Conclusion: We demonstrate a defective anti-inflammatory function of ESRD-HDL due to incorporation of SAA in HDL that may provide a molecular explanation for the cardiovascular mortality in ESRD and can be used as novel cardiovascular biomarker. Unter oralem Prednisolon kommt es zum Rückgang der auch nach Cholezystektomie erhöhten Cholestasewerte und der Thoraxschmerzen. In den Kontrollen sind Troponin-T negativ, Cardiac-MR-und Thorax-CT unverändert, der Augenbefund jedoch progredient.

Nach einer frustranen Therapieergänzung mit Azathioprin wird eine Anti-TNF-Alpha-Therapie unter Prednisolon-Erhaltungsdosis begonnen. Es folgt eine komplette Remission des Augenbefalls.

Nach acht Monaten kommt es jedoch zu Nebenwirkungen der TNF-Alpha-Blockade und neuerlichen Stenokardien. Hs-Troponin-T Messungen sind wiederholt positiv. Nach einem Steroidstoß normalisieren sich diese Laborwerte wieder. Die Patientin ist beschwerdefrei. Das (im Intervall durchgeführte) Herz-MR zeigt sich wie das Thorax-CT stabil, die Lungenfunktion unauffällig.

Zur weiteren Therapie wird nun mit einer Methotrexat-Behandlung unter Steroidreduktion begonnen.

Der geschilderte Fall birgt Hinweise, dass hier eine Korrelation zwischen den Troponin-Erhöhungen und der Entzündungsaktivität der Sarkoidose bestehen könnte. Studien liegen diesbezüglich kaum, für hs-Troponin gar nicht vor. Background: Autoimmune pancreatitis (AIP) is a benign form of chronic pancreatitis and is part of the IgG4-assosiated fibroinflammatory syndromes. The clinical features of AIP include pancreatic and extrapancreatic manifestations. One important pancreatic manifestation is Diabetes mellitus. Imaging similarities of AIP and pancreatic cancer may lead to misdiagnosis and unnecessary surgery. The revised Japanese Diagnostic Criteria from 2006 contain three items for the diagnosis of AIP: (1) Enlargement of the pancreas and irregular narrowing of the main pancreatic duct on radiology;

(2) high serum gammaglobulin IgG or IgG4 levels or the presence of autoantibodies; and (3) interlobular fibrosis and prominent lymphocyte and plasma cell infiltration histologically.

Patients: We describe 2 cases of confirmed AIP seen at our Department:

In the first patient (female, age 70 years.) CA19-9 was abnormally high, but the pancreas was of normal size on computed tomography. Subsequent pancreatic biopsy confirmed the presence of AIP. Diabetes mellitus and arthritis of both hands were additional comorbidities. Corticoids for induction and methotrexate for maintenance therapy resulted in complete remission of AIP and arthritis.

The second patient (female, age 63 years.) presented with upper abdominal pain and pathological elevated blood glucose levels. Diabetes mellitus de novo was diagnosed. MRI of pancreas showed typical radiologic signs for AIP and an additional pancreatic biopsy verified the diagnose.Induction therapy with corticosteroids and methotrexate for maintenance therapy resulted in remission of AIP and stabilisation of diabetes.

Conclusion: As AIP mimics pancreatic cancer clinically and radiologically, it is a multidisciplinary diagnostic challenge for radiologists, internists and surgeons. The combined initial steroid and methotrexate therapy may be as efficient for AIP as for other autoimmune diseases. Background: Osteoarthritis (OA) is a widespread and common disease in the middle aged to elderly population. The course of disease is associated with pain and functional impairment leading to invalidity. Overweight, mechanical stress and genetic factors enhance the progression of the disease. We postulate that epigenetic modulation of gene expression changes throughout the different stages of OA.

Methods: Cartilage specimens collected from macroscopically healthy and degenerated areas of surgically replaced knee joints were processed for DNA extraction and immunohistochemistry to evaluate the histological grading of the disease. The methylation status of insulin like growth factor (IGF-2, IGF-3) and interleukin-32 (IL-32) was analyzed using a methylation array. The expression of these target genes was determined by qPCR before and after in vitro stimulation with interleukin-1.

Results: Promoters of IGF-2,IGF-3 and IL-32 were significantly (p < 0.05) hypomethylated in late stage OA. This correlated with an increased gene expression in chondrocytes from high-grade OA probes.

Conclusion: In progressive stages of osteoarthritis, genes for IGF-2, IGF-3 and IL-32 are hypomethylated. Our results may help to proceed in OA research understanding pathogenetic mechanisms and even to develop sufficient therapies in the future.

Neurosarcoidose -eine seltene Manifestation der Sarkoidose Background: Sensitive biomarkers for early differentiation between SIRS and sepsis are urgently needed. Soluble urokinase plasminogen activator receptor (suPAR) levels reflect inflammation and elevated suPAR levels have been described in several infectious-and inflammatory diseases. Determined suPAR levels were compared to parameters for infection from the routine.

Methods: The study included 140 patients consisting of 63 patients with bacteremia divided into study group 1 (S. aureus and Streptococcus spp.) and study group 2 (gram-negative bacteria). Control group included 77 patients with SIRS having negative blood cultures. Patients with previous anti-infective therapy were excluded from the control group. Samples were taken simultaneously with initial blood cultures. suPAR, PCT, IL-6, CRP, and WBC were determined.

Results: Elevated suPAR levels were found for the SIRS collective (mean 8,025 (SD ± 3,783) when compared to values previously published for healthy controls (median 3.38 ng/mL). Statistical analysis using Mann-Whitney U test revealed that suPAR was significantly higher in gram-positive (median 8.11; p = 0.006) and gram-negative sepsis (median 9.62; p < 0.001) than in the control group (SIRS but negative blood cultures; median 5.65). Difference was also significant for PCT (group1, p = 0.001; group2, p = 0.002) and IL-6 (group1, p < 0.001; group2, p = 0.017). ROC curve analysis revealed an AUC of 0.726 for suPAR in differentiating SIRS patients with bacteremia from patients without.

Conclusion: suPAR has potential in predicting bacteremia in SIRS patients. PCT and IL-6 seem to be the favorable prognostic parameter for bacteremia caused by S. aureus and Streptococcus spp. as both parameters were significantly higher when bacteremia was caused by these microorganisms. suPAR on the other hand seems to have more potential to predict gram-negative bacteremia. Preliminary results suggest that suPAR may help to predict bacteremia in clinical routine.

Infektiologie abstracts ÖGIM Background: Catheter colonization with a cut off level of 1000 organisms/ml catheter blood is considered to be a forerunner of central venous catheter related bloodstream infections (CRBSI). This prospective trial was undertaken to evaluate whether the PNA FISH test could serve as a screening tool to detect CRBSI in a subclinical stage in hemodialysis patients with central venous catheters (CVCs) used with non antimicrobial locking anticoagulants (heparin, citrat 4 %).

Methods: Fifty-five hemodialysis patients with 60 catheter episodes were prospectively investigated. Screening for CRBSI was performed by PNA FISH test with universal hybridisation probes (for detection of all relevant bacteria and fungi) three times a week using EDTA blood from both lumina of CVCs obtained prior to hemodialysis. In addition blood samples were quantitatively cultured on chocolate agar. If CRBSI was clinically suspected, routine investigation was performed by the Gram stain/acridine orange leucocyte cytospin (AOLC) test, differential time to positivity (DTP) and Brun Buisson method.

Results: 2972 blood samples were investigated. With routinely performed investigations 2 CRBSIs were detected in 3691 catheter days resulting in a CRBSI rate of 0,5/1000 catheter days. Both of these 2 CRBSIs were detected by PNA FISH screening before the diagnosis was established by routine measures. In 58 catheter episodes no CRBSI could be detected by routinely performed tests. In three of these catheter episodes PNA FISH screening was false positive. The sensitivity and specificity of PNA FISH screening were 100 and 95 %, the PPV and NPV were 40 and 100 %.

Conclusion: Screening of blood drawn from CVCs prior to hemodialysis by PNA FISH helps to detect patients at risk for clinically evident CRBSI. Thus, patients with positive screening should be thoroughly observed with regard to development of clinically evident CRBSI. Patients with negative PNA FISH screening tests are unlikely to develop CRBSI. Wir berichten von einem 26-jährigen, bulgarischen Patienten, welcher deutlich bewusstseinsgetrübt mit Fieber (39° C), Meningismus und Beugekrämpfen an unserer Überwachungsstation stationär aufgenommen wurde. Weiters war ein kleinfleckiges, kon-P88 P89 P90 abstracts ÖGIM fluierendes Exanthem (Gesicht, Brust, Rücken), eine Enanthem der Mundschleimhaut und eine blutige Bindehautentzündung auffällig. Auch respiratorisch zeigte sich der Patient kompromittiert, war jedoch zunächst unter Insufflation von 4 L/min O 2 kompensiert. Die Angehörigen des Patienten berichteten, dass die ersten Symptome (Exanthem, Fieber, Husten und Rückenschmerzen) vor drei Tagen zu beobachten waren. Am Tag der Aufnahme kam es zu einer plötzlichen Bewusstseinseintrübung. Wegen hochgradigen Verdachts auf eine Meningoencephalitis erfolgte eine Lumbalpunktion. Im Liquor ließen sich Parameter, die für eine Virusinfektion sprechen (Zellzahl: 36/3 GF, Glucose: 780 mg/l, Laktat: 2,9 mmol/l, Protein: 1802 mg/l) nachweisen, so dass zunächst eine antivirale Therapie mit Acyclovir initiiert wurde. Aufgrund der erheblichen Unruhe des Patienten erfolgte über einige Stunden eine Sedierung mit Midazolam. Eine in weiterer Folge durchgeführte Magnetresonanztomographie des Gehirns zeigte unauffällige Verhältnisse. Am 3. Tag des stationären Aufenthalts hatte der Patient wieder sein volles Bewusstsein erlangt, war jedoch noch sehr schwach. Bei weiterhin bestehender Oxygenierungsstörung, ansteigenden Entzündungsparametern (CRP 162 mg/l) und einem im Lungenthoraxröntgen neu aufgetretenen Verdichtungsareal im linken Mittel-/Unterfeld wurde eine bakterielle sekundäre Pneumonie diagnostiziert, welche mit Cefuroxim behandelt wurde. Nach 9 Tagen konnte der Patient beschwerdefrei entlassen werden. Immunserologisch ließ sich die Verdachtsdiagnose einer akuten Maserninfektion bestätigen (Masern IgM positiv, IgG negativ). Ein molekularbiologischer Nachweis von Virus-RNA sowie der Versuch, das Virus elektronenmikoskopisch abzubilden, gelang nicht. Aussenanamnestisch konnten wir erheben, dass der Patient sein Bett mit einem gesicherten Masernfall geteilt hatte.

Diagnose: Postinfektiöse Encephalomyelitis, hervorgerufen durch Masern. Grundlagen: Weltweit sind jährlich etwa 2,5 Mio. Menschen von Bissen durch Giftschlangen betroffen, davon sterben mehr als 100.000. Von über 3.200 bekannten Schlangenarten wird ca. ein Drittel zu den Giftschlangen gerechnet. Die bei Vipernbissen entstehende Koagulopathie ist letzten Endes der wesentliche Faktor für Morbidität und Mortalität, während bei anderen Schlangen vorwiegend Neuro-oder Zytotoxine zu schweren Vergiftungserscheinungen führen können. In Österreich sind hochgiftige Schlangen nicht heimisch, Vergiftungen treten daher sehr selten auf. Im Folgenden berichten wir über den Verlauf eines Bisses mit der in Afrika heimischen schwarzgrünen Buschviper (Atheris nitschei, engl. Great Lakes bush viper). Atheris gehört zu der Familie der Viperiden. Die Verbreitung begrenzt sich auf Südwest-Uganda, Nordwest-Tansania, West-Ruanda und Burundi sowie auf die Demokratischen Republik Kongo. Sie kommt in Hochlandgebieten vor. Dort findet man diese Art in Papyrus-, Elefantengrasbeständen, in Büschen und Wäldern. Die schwarzgrüne Buschviper wird i. d. R. nicht länger als 70 cm, teilweise erreicht sie nur eine Länge von 30 cm.

Kasuistik: Ein 39-jähriger Mann wurde von einer schwarzgrünen Buschviper in den linken Zeigefinger gebissen. Die Buschviper wurde etwa 4 Wochen zuvor in Afrika gefangen und zum Verkauf weiter nach Europa transportiert. Unmittelbar nach dem Biss kam es zu Allgemeinsymptomatik mit Schwindel und kurzer Bewusstlosigkeit. Etwa 5 Stunden nach dem Biss wurde er auf unserer Intensivstation aufgenommen. Bei Aufnahme war der Patient voll ansprechbar, neurologisch unauffällig sowie kardiorespiratorisch stabil (RR 120/60 mmHg, SaO 2 95 %, Puls 100/min) und afebril. Im Bereich des linken Zeigefingers zeigte sich eine etwa 3 cm lange große Nekrose. In den blutchemischen Befunden auffällig ein nicht nachweisbares Fibrinogen, mit nicht messbarer PTZ und PTT, normales AT III, geringgradig verminderte Thrombozytenzahl, normale Erythrozytenzahl und eine erhöhte Leukozytenzahl bei normalem CRP. In der ROTEM Analyse zeigte sich eine verlängerte Gerinnungszeit (CT), Gerinnungsbildungszeit (CFT) sowie eine stark verminderte Gerinnselfestigkeit (MCF) im EXTEM und INTEM als Zeichen einer verminderten Hämostase Kapazität, im FIBTEM stellte sich eine Nulllinie als Ausdruck des nicht nachweisbaren Fibrinogen bzw. der Störung der Fibrinpolymerisierung dar. Es erfolgte initial eine Schocktherapie mit Ringerlaktat bei Hypotension, eine schmerzstillende Therapie mit Paracetamol, Diclofenac und Sufentanil, eine Stressulcusprophylaxe mit Esomeprazol, eine konservative lokale Therapie mit Ruhigstellung, Armhochlagerung, täglichen Verbandswechseln nach antiseptischer Wundbehandlung, sowie die Gabe von Fibrinogen zur Behandlung der Koagulopathie. In den ersten 24 Stunden wurden insgesamt 10 g Fibrinogen verabreicht um das Fibrinogen auf 72 mg/dl anzuheben. Es kam damit auch zu einer Normalisierung der PTT und PTZ. In den nächsten 24 Stunden war nochmals 2 g Fibrinogen notwendig. Bei Fieber und steigenden Entzündungsparametern wurde am 2.Tag eine Antibiose mit Sulbactam/Ampicillin begonnen und am 5. Tag um Clindamycin erweitert. Eine Tetanusauffrischung war bei bestehendem Impfschutz nicht notwendig. Lokal entwickelte sich am linken Zeigefinger eine prall gefüllte livide verfärbte Bulla, ein ausgeprägtes Ödem und Hämatom am linken Unter-und Oberarm bis zur Achsel reichend, mit Maximum der Ausdehnung nach 4 Tagen, ohne Ausbildung eines Kompartmentsyndroms. Nach 6 Tagen wurde der Patient auf die Normalstation transferiert, nach 8 Tagen in eine ambulante Pflege entlassen.

Diskussion: Bisse durch Giftschlangen können zu sehr unterschiedlichen Vergiftungserscheinungen führen. Giftschlangenbisse sind extrem schmerzhaft und gehen mit zahlreichen lokalen und systemischen Veränderungen einher. In unmittelbarer Nähe zur Bissstelle bilden sich bei Vipernbissen so auch in unserem Fall, Ödeme, Hämorrhagien und Nekrosen. Im Gift enthaltene Hyaluronidasen (sog. Spreadingfaktoren) sorgen dabei durch eine Gewebsauflockerung dafür, dass sich das Gift besser im Gewebe verbreiten kann. Durch Zytotoxine entstehen nahe der Bissstelle Blasen und Nekrosen. Massive Ödembildungen mit bis zu 3 Litern Flüssigkeitseinlagerung können in kurzer Zeit zu einem Volumenmangelschock führen. Die Zusammensetzung der zusätzlich systemisch wirkenden Schlangengifte variiert stark von Art zu Art und sogar von Individuum zu Individuum und hängt von zahlreichen Faktoren wie Herkunft, Alter, Ernährungsweise und Haltungsbedingungen ab. Nichtsdestoweniger sind die Gifte in gewisser Hinsicht für die jeweilige Schlangenfamilie charakteristisch: Beispielsweise wirkt das Gift der Vipern (Viperidae) eher auf das Gerinnungssystem, während Giftnattern (Elapidae) durch die in ihrem Gift vorhandenen Neurotoxine insbesondere das Nervensystem des Opfers angreifen und beim Menschen zu vielfältigen neurologischen Ausfallerscheinungen führen können.

Die in der schwarzgrünen Buschviper enthaltenen Gifte sind bislang nicht komplett aufgeklärt. Grundsätzlich bestimmen Proteasen wie sogenannte Hämorrhagine das Vergiftungsbild nach Vipernbissen. Sie hydrolysieren den v. a. aus Kollagen bestehenden Halteapparat der kleinsten Gefäße. In weiterer Folge können Erythrozyten durch die nun geschwächte Basalmembran, noch leichter in das umgebende vorgeschädigte Bindegewebe austreten. Zu beachten ist auch die Wirkung von Proteasen auf das Kininsystem. In kürzlich durchgeführten Untersuchungen des Atheris-Gifts P91 abstracts 43. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin 593 ÖGIM 1 3 wurden Proteine beschrieben die Prekursor Sequenzen von Bradykinin potenzierenden Peptiden (BPP) und C-type natriuretischen Peptiden (CNP) ähneln, welche bekannt sind das Kreislaufsystem über besondere Metalloproteasen und Rezeptoren beeinflussen zu können (Erhöhung der venolären Permeabilität, Senkung des arteriellen Drucks). Kreislaufprobleme konnten bei unserem Patienten jedoch nur initial beobachtet werden.

Eine Recherche in PUBMED ergab keine bislang publizierten Vergiftungsfälle. In persönlichen Fallschilderungen werden Gerinnungsstörungen einhergehend mit lebensbedrohlichen Blutungen und lokale Nekrosen berichtet. Zwar wird bei massiven Gerinnungsstörungen auf die Möglichkeit der Gabe eines (oft nicht unmittelbar verfügbaren) polyvalenten Antiserums gegen gerinnungstoxische Schlangen (Vipera, Cerastes, Echis) hingewiesen, aber ein spezifisches Antiserum bei Atheris-Bissen ist nicht vorhanden.

Wie unser Fall zeigt, konnte durch Substitutionstherapie mit Gabe von Fibrinogen und Schocktherapie ebenfalls eine Stabilisierung erzielt werden, ohne die Komplikationen eines Antiserums zu riskieren. Zudem wurde demonstriert, dass das Gift von Atheris nitschei potentiell eine lebensbedrohliche Hypotension, Afibrinogenämie und Thrombopenie hervorrufen kann.

Renal replacement therapy in patients with acute liver failure abstracts ÖGIM

Der Gesamtscore reichte von 0 bis 12. Der Saxon-Test wurde am gleichen Tag durchgeführt. Die Resultate des Saxon-Tests wurden in Terzilen(< 1241 ml (A), 1241-2364 ml (B) und > 2364 ml (C)) aufgeteilt, da bisher kein Grading für diesen Test verfügbar ist. SPSS v.18.0 wurde zur Analyse mittels Kruskall-Wallis-und Mann-Whitney-U-Test verwendet. Ergebnisse: Der mediane semiquantitative Score war 6 (0-12) und die mediane Speichelproduktion lag bei 1,66 g/2 min

Dementsprechend hatten Patienten aus der untersten Terzile des Saxon-Tests ein siginfikant höheres Grading

im Vergleich zu Patienten der mittleren Terzile

p = 0,003) und der obersten Terzile

Der Vergleich zwischen Patienten der mittleren und der höchsten Terzile ergab ein p = 0,091. Schlussfolgerung: Pathologische Resultate der Sialoszintigraphie korrelieren mit der Beeinträchtigung der Speichelsekretion bei Patienten mit pSS

Grundlagen: Die real-time Sonoelastographie (SElasto) wird zur Einschätzung der Gewebefestigkeit angewendet. In dieser Studie wurde der Wert der SElasto zur Untersuchung der Speicheldrüsendysfunktion beim primären Sjögren Syndrom (pSS) geprüft.Methodik: Prospektive Studie an 37 pSS Patienten [mittleres Alter 59 Jahre; 92 % weiblich; Krankheitsdauer im Median 3.1 Jahre]. Das Ergebnis der Speicheldrüsenszintigraphie (Szinti) wurde als Goldstandard der Speicheldrüsenfunktion herangezogen und von 0 = normale Funktion bis 12 = schwere Funktionsstörung aller 4 Kopfspeicheldrüsen bewertet. In der B-Mode Sonographie und in der SElasto wurden pathologische Veränderungen ebenso mit Hilfe von Scores (B-mode 0-48, SElasto 0-16) bewertet. Die Interobserver Variabilität wurde bei 30 % der Patienten getestet.Ergebnisse: Der mittlere Szinti Score betrug 6,0 (± 4,3). Ein Funktionsverlust von ein, zwei oder vier Kopfspeicheldrüsen wurde bei 5,3 %, 17,5 % bzw. 19,3 % der Patienten beobachtet. Der B-Mode (corr coeff 0,65, p < 0,001) und der SElasto Score (corr coeff 0,39, p = 0,02) korrelierten mit dem Szinti Score. Patienten mit Funktionsverlust in zumindest einer Speicheldrüse wiesen höhere B-Mode [Median 27,5 (Spannbreite 10,0-44,0) vs. 12,0 (2,0-6,9) p < 0,001] und SElasto Scores [7,0 (3,0-12,0) vs. 6,0 (2,0-7,0) p = 0,032] auf als Patienten mit funktionstüchtigen Drüsen. In der ROC Kurvenanalyse wurde eine AUC von 0,91 (95 % CI 0,8-1,0, p < 0,001) und 0,73 (0,56-0,89, p = 0,03) für die B-Mode Sonographie und die SElasto zur Identifikation von Patienten mit funktionsgestörten Kopfspeicheldrüsen gefunden. Die Reproduzierbarkeit der B-Mode und SElasto Sonographie war gut mit ICC Werten von 0,926 (95 % CI 0,565-0,983) bzw. 0,934 (0,787-0,981). Für die Szinti wurde ebenso eine geringe Variabilität der Ergebnisse beobachtet (kappa 0,871).Schlussfolgerung: Strukturelle Veränderungen und eine erhöhte Gewebefestigkeit in der Sonographie sind mit der Funktionsstörung der Kopfspeicheldrüsen beim pSS assoziiert.Sonoelastography zur Einschätzung der Speichelproduktion beim primären Sjögren-Syndrom Ergebnisse: Eine 52-jährige Patientin wurde wegen einer intensivpflichtigen Serum-Hypokaliämie (1,6 mmol/l) mit Muskelparalyse bei einem Serum-Kreatinin von 1,3 mg/dl nephrologisch vorgestellt. Zudem war Serum-IgG mit 20,6 g/l (normal 7-16) vermehrt. Eine metabolische Acidose (pH 7,21; BE-17,5) mit normaler Serum-sowie positiver Urin-Anionenlücke bei einem Harn-pH von 7,5 deutete auf eine distale renal tubuläre Acidose (RTA-I) hin. Die vorrangig tubuläre Proteinurie (0,5 g/24 h) mit IgG-Exkretion und massiver ß2-Mikroglobulin Ausscheidung (31500 µg/l; normal bis 300) wiesen auf eine interstitielle Nephritis hin. Ein pathologischer Schirmertest (re. 1 mm; li. 0 mm) und ein pathologischer Saxontest (1,0 g/2 min) sowie eine pathologische Speicheldrüsenszintigraphie erhärteten bei subjektiv seit 15 Jahren bestehender Xerophthalmie und Xerostomie den Verdacht auf ein Sjögren-Syndrom. Dies führte zusammen mit dem Nachweis von Ro-und La-Antikörpern und einer pathologischen Speicheldrüsenbiopsie zur Diagnose eines primären Sjögren-Syndroms als Ursache der schweren Hypokaliämie. Unter täglicher Zufuhr von Kaliumcitrat/-carbonat (117 mmol K + ) und oraler Glukokortikoidgabe konnte eine suffiziente Symptomkontrolle bei Normokaliämie erreicht werden.Schlussfolgerung: Bei Hypokaliämie, Harn-pH > 5,5, metabolischer Azidose mit normaler Serum-und positiver Urin-Anionenlücke als Ausdruck einer RTA Typ I sollte, insbesondere bei Vorliegen einer Sicca-Symptomatik, ursächlich an eine interstitielle Nephritis im Kontext eines Sjögren-Syndroms gedacht werden.Evaluierung des Ankylosing Spondylitis Disease Activity Score (ASDAS) anhand der radiologischen Progression Grundlagen: Die ankylosierende Spondylitis (AS) ist eine entzündliche Wirbelsäulenerkrankung. Für die Messung der Krankheitsaktivität stand bisher nur der ausschließlich Patienten-orientierte Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) zur Verfügung. In dieser Arbeit wird untersucht, ob der neu entwickelte und auch die objektiven Entzündungsparameter (CRP und BSG) enthaltende Ankylosing Spondylitis Disease Activity Score (ASDAS) die radiologische Progression der AS besser vorhersagen kann als der BASDAI.Methodik: Es wurden die Daten von 58 PatientInnen für die Auswertung verwendet. Die für die Berechnung des ASDAS notwendigen Parameter Rückenschmerz, Morgensteifigkeit, globale Beurteilung durch den Arzt, Anzahl geschwollener/druckschmerzhafter Gelenke, Müdigkeit, CRP und BSG wurden retrospektiv aus dem internen Dokumentationssystem (RCQM) extrahiert. Zudem wurden Röntgen der Wirbelsäule, im Mindestabstand von zwei Jahren, von zwei unabhängigen Radiologen mittels modifiziertem Stoke Ankylosing Spondylitis Spine Score (mSASSS) analysiert und die Daten mittels Spearman-Korrelation statistisch ausgewertet.Ergebnisse: Das mittlere Alter der PatientInnen betrug 49,5 Jahre (SD = 10,8), der mittlere Beobachtungszeitraum 3,23 Jahre (SD = 1,19), der mittlere ASDAS-CRP 1,99 (SD = 1,03), der mittlere ASDAS-BSG 1,99 (SD = 0,97), der mittlere BASDAI 3,85 (SD = 2,12) sowie mittlere Anstieg des mSASSS pro Jahr 1,32 (SD = 1,26), 87,3 % waren HLA-B27 positiv.Die radiologische Progression (∆mSASSS) pro Jahr korrelierte signifikant mit dem ASDAS-CRP (r = 0,243; p = 0,036*) und dem ASDAS-BSG (r = 0,289; p = 0,015*). Keine Korrelation gab es zwischen dem BASDAI und dem ∆mSASSS/Jahr (r = 0,220; p = 0,052).Schlussfolgerung: In dieser Arbeit wurde gezeigt, dass der neu entwickelte ASDAS besser in der Lage ist die radiologische Progression der AS an der Wirbelsäule vorherzusagen als der BASDAI. to Clostridium difficile infection Background: This prospective cohort study was performed to analyse the effect of CDI on the risk of pre-discharge all-cause death in all inpatients with CDI compared to all inpatients without CDI during the year 2009 in a single hospital.Methods: CDI was defined as by the European Society of Clinical Microbiology and Infectious Diseases. Data were collected using medical charts in CDI patients and hospital discharge data in non-CDI and CDI patients. The effect measures of CDI on the risk of predischarge all-cause death computed were risk ratio, attributable risk, mortality fraction (%) and population attributable risk percent. Co-morbidity was categorized by use the Charlson's co-morbidity score. A stratified analysis and a Possion regression model were applied to adjust for effects of the risk factors sex, age and severity of comorbidity.Results Background: We describe two linked cases of botulinum toxin intoxication to provide the clinician with a better idea about how botulism cases may present, since early diagnosis and treatment is crucial in botulism.Botulinum toxin is the strongest neurotoxin known. Although in industrialized societies there is a very high standard of quality control in the industrial food production, this is not the case in homemade or imported products which thus can be a source of botulinum toxin.Methods: We review the available literature the compiled clinical data and observations. Results: After a slow onset of clinical signs a married couple living in Vienna presented with dysphagia, difficulties in accommodation, inability to sweat, urinary and stool retention, dizziness and nausea. The performed general laboratory screening did not reveal any significant findings. They suffered intoxication with botulinum toxin type B. Botulism is a rarely occurring disease in Austria. In the last 21 years there were only twelve reported cases, none of which took place in Vienna. We present the first case of botulism in 21 years.Conclusion: Both patients went to a general practitioner as well as several specialists before they were sent to and correctly diagnosed at our outpatient department. To avoid long delays between intoxication and diagnosis we think it is crucial to advert to the complex symptoms a non-severe intoxication with botulinum toxin can produce, especially since intoxications have become rare occurrences in the industrialized societies due to the high quality of industrial food production. Background: This prospective observational multicenter study was conducted to investigate the age dependent epidemiology of pneumonia with a special emphasis on potential risk factors for mortality.

Methods: The present data were derived from the Austrian Pneumonia Network (APNET), comprising 9 Departments for Internal Medicine with a total of 1011 hospital beds. All inpatients diagnosed with pneumonia during 2011 were followed until discharge. Identification of microorganisms was performed according to local standard methods. Data of the two age groups (< 65 years and ³ 65 years) of patients were compared by Mann Whitney test for continuous and the Chi-square test for categorical data. Risk factors for P86 P87 P85 abstracts 43. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin 591 hospital mortality were evaluated by univariate and multivariate analyses.Results: Overall, 1956 patients were included. Older patients a higher incidence of dyspnoea, pleural effusion and confusion at presentation. The overall all cause hospital mortality was 10.4 %, and was higher in patients ≥ 65 (12.7 %) than in patients < 65 years of age (5.0 %; p < 0.001). Streptococcus (S.) pneumoniae was the most important pathogen in both age groups. Enterobacteriacaeae were revealed significantly more often in patients ≥ 65 years. Age ≥ 65 years, chronic heart failure and neurological disease increased the risk of hospital mortality 1.96 (95 % CI 1.19-3.20), 1.59 (95 % CI 1.10-2.29), and 1.7 (95 % CI 1.19-2.41) fold, respectively.Conclusion: Pneumonia patients with chronic heart failure, neurological disease and age > 65 years could benefit from intensified care due to increased risk of in-hospital death. Risk factors of severity (need for surgical intervention, intensive care or fatal outcome) were analysed in hospital-acquired Clostridium difficile infection (CDI) in a 777 bed community hospital. In a prospective analytical cross-sectional study, age (³ 65 years), sex, CDI characteristics, underlying diseases, severity of co-morbidity and PCR ribotypes were tested for associations with severe CDI. In total, 133 cases of hospital-acquired CDI (mean age 74.4 years) were identified, resulting in an incidence rate of 5.7/10.000 hospital-days. A recurrent episode of diarrhoea occurred in 25 cases (18.8 %) and complications including toxic megacolon, dehydration and septicaemia in 69 cases (51.9 %). Four cases (3.0 %) required ICU admission, one case (0.8 %) surgical intervention and 22 cases (16.5 %) died within the 30-day follow-up period. Variables identified to be independently associated with severe CDI were severe diarrhoea (odds ratio [OR]: 3.64, 95 % confidence interval [CI]: 1.19-11.11, p = 0.02), chronic pulmonary disease (OR: 3.0, 95 % CI: 1.08-8.40, p = 0.04), chronic renal disease (OR: 2.9, 95 % CI: 1.07-7.81, p = 0.04) and diabetes mellitus (OR: 4.30, 95 % CI: 1.57-11.76, p = 0.004). The case fatality of 16.5 % underlines the importance of increased efforts in CDI prevention, in particular for patients with underlying diseases.

Microbiological screening for detection of central venous catheter related bloodstream infections in patients undergoing hemodialysis J. Wagner 1 , T. Valentin 1 , M. Hönigl 1 , G. Schilcher 2 , W. Ribitsch 2 , J. Horina 2 , A. R. Rosenkranz 2 , R. Krause 1 Background: Acute Liver Failure (ALF) is a severe illness, which can lead to multiple organ failure and death. Current guidelines recommend not initiating renal replacement therapy (RRT) in ALF patients with renal failure without liver transplant option. However, clinical data are scarce.Methods: Binational study of patients with ALF admitted between 2005 and 2010. SOFA and SAPS II score on admission, as well as mortality after 28d were assessed. For subgroup analysis, patients were stratified for liver transplant listing status. ALF was defined according to international consensus criteria (INR > 1.5 and presence of hepatic encephalopathy).Results: 79 patients with ALF were included in the analysis. Main underlying causes of ALF were paracetamol intoxication(19 %), viral hepatitis(19 %), non-paracetamol drug toxicity (19 %), amanita (14 %) and other causes (29 %). 40 % of the patients were male, median age was 49 years. RRT was initiated in 48 % of the patients. Patients requiring RRT had significantly higher SOFA and SAPS II score on admission, higher rate of hepatic encephalopathy Grade 3/4 and mechanical ventilation. Mode of RRT did not influence outcome. Higher SOFA score on admission and higher lactate levels on admission were independent predictors for RRT during the course of the disease in multivariate regression. 28d mortality in patients requiring RRT was 45 %. In patients listed for LTX, 28d mortality did not differ significantly in patients with or without RRT (27 vs 15 %, p = ns). In contrast, necessity of RRT was associated with significantly higher mortality rates in patients not listed for transplantation (65 vs 16 %, p < 0.05). Multivariate regression revealed vasopressor use as only independent predictor for 28d mortality in patients requiring RRT.Conclusion: Advanced severity of disease is the main risk factor for necessity of RRT in ALF. Although outcome in patients requiring RRT not listed for LTX is worse, RRT should not kept back for these patients a priori.